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ABSTRACT OF THE DISSERTATION
Genetic Factors That Contribute to the Pathogenesis of Amyotrophic Lateral Sclerosis
By
Janet Elizabeth Cady
Doctor of Philosophy in Biology and Biomedical Sciences
Human and Statistical Genetics
Washington University in St. Louis, 2015
Assistant Professor Matthew Harms, Chair
Professor Alison Goate, Co-Chair

Amyotrophic lateral sclerosis (ALS) is fatal neurodegenerative disease for which there is
no cure. The only treatment available extends survival by only a matter of months. There are
over 20 genes that are known to cause ALS. Over half of the ALS cases with a family history of
disease (FALS) can be explained by mutations in known ALS genes with hexanucleotide repeat
expansions in C9ORF72 accounting for 40% of families. However roughly 90% of cases have no
family history of disease (sporadic ALS or SALS) and a much smaller proportion (10%) of these
cases can be explained by mutations in known ALS genes. Understanding the genetic factors that
cause ALS or influence its progression will help us understand the cellular pathways involved in
disease and identify potential therapeutic targets.
We used a pooled-sample sequencing approach to identify mutations in 17 ALS genes in
a cohort of FALS and SALS patients to investigate the contribution of these genes to SALS,
including the role of rare variants and the effect of mutations in multiple ALS genes in an
individual. We identified potentially pathogenic mutations in 64.3% of familial and 27.8% of
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sporadic subjects. 3.8% of subjects had mutations in more than one ALS gene and these
individuals on average had onset 10 years earlier than those with mutations in only one ALS
gene (p=0.0046). There were no individual rare variants that were significantly associated with
sporadic ALS, but rare variants in SOD1 were cumulatively more common in SALS subjects.
In addition we investigated the genetic background and stability of C9ROF72 repeat
expansions in ALS. The presence of a risk haplotype shared between all expansion-carriers led to
the prevailing idea of a founder expansion event, however this shared haplotype also supports the
hypothesis of a genetic background that is more prone to expansion. We identified a rare variant
rs147599399 on this genetic background that is present in some expansion carriers and some
non-expansion carriers, indicating that the expansion arose on at least two separate occasions.
This raises the possibility that C9ORF72 repeat expansions in sporadic ALS could be the result
of de novo expansions on the risk haplotype. Furthermore we showed that expansion carriers
with rs147599399 minor allele had longer survival than expansion carriers without the SNP
(p=0.00047), indicating that the genetic background surrounding the C9ORF72 influences the
effects of the expansion.
We performed Southern blotting to explore the size and stability of C9ORF72 repeat
expansions. There was a high degree of somatic instability and instability in transmissions
between families. There was no difference between expansion sizes in symptomatic and
asymptomatic expansion carriers in families an there was no correlation between expansion size
in any patient tissues and any clinical characteristics. These results need to be confirmed in a
larger sample cohort, but suggest that expansion size alone doesn’t determine pathogenicity of
C9ORF72 repeat expansions.

xii

Lastly we examined the candidate gene TREM2 as a risk factor for ALS. This gene is
involved in regulation of microglial activity, which is a known component of ALS pathogenesis,
and the rare variant p.R47H was recently associated with risk Alzheimer’s disease. We found
that the same p.R47H variant was significantly associated with ALS in our cohort and that
expression of TREM2 was increased in ALS patients and SOD1 mutant mice compared to
controls. A variant in the related gene TREML4 was marginally associated with ALS, but the
effect of this variant is unknown. Mutations in the TREM genes provide a genetic link between
to the neuro-inflammatory component of ALS and suggest other genes involved in microglial
activation are good candidates for novel variant identification.
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Chapter 1
Background and significance
1.1 Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease is the most
common form of motor neuron disease. Motor neurons in the brain and spinal cord are affected
resulting in loss of motor function, paralysis, muscle wasting, and difficulty breathing and
swallowing. Death typically occurs after 3-5 years due to respiratory failure.1–5 The disease can
have either limb onset, affecting the arms or legs first or bulbar onset, affecting speech,
swallowing and breathing first. There is no cure for ALS. Riluzole is the only available
treatment and only slows the progression of symptoms.6
Average age of symptom onset ranges from 40-70, however this can vary greatly with
cases in their 20’s and even cases of juvenile onset.7–12 ALS is diagnosed according to the El
Escorial criteria13 which include the presence of signs of upper motor neuron degeneration
(weakness, wasting, and fasciculations), signs of lower motor neuron degeneration (increased
reflexes, spasticity), progressive spread of symptoms, and the absence of other disease that could
explain the clinical findings. The diagnosis can be definite, probable, possible, or suspected
depending on the strength of clinical evidence.
Disease progression is typically measured using the ALS functional rating scale
(ALSFRS)14. This scale ranks the patient’s functional impairment using a five-point scale on 12
different tasks with 4 being no loss of function and 0 being complete loss of function. These
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score are summed across all 12 tasks to obtain the ALSFRS score. The highest possible score is
48 and the lowest is 0.
Cognitive changes are common in ALS ranging from mild cognitive impairment to
frontotemporal dementia (FTD). ALS and FTD, also called frontotemporal lobar degeneration
(FTLD), are considered to fall on a spectrum. FTD is present is roughly 25% of cases of ALS
while about 50% of FTD cases also have motor neuron degerentation.15 Even within families,
some members can develop either pure ALS, ALS with FTD or pure FTD.
Estimates of the prevalence vary by population with a systematic literature review
reporting a range of 1-11.3/100,000 (median =4.48).16 Prevalence in the United States was 2.93.9/100,00017–19. Incidence ranged from 0.3-3.6 (median=1.9) worldwide with two studies in the
U.S reporting 1.7 and 1.8.16 When comparing retrospective and prospective studies, prospective
studies tended to result in higher estimates of both prevalence and incidence.16
There is a family history of disease (typically with an affected first or second degree
relative) in 5-10% of cases (FALS)20–22, although this can difficult to ascertain. The late onset of
disease increases the likelihood of death from unrelated causes before developing symptoms,
obscuring possible inheritance patterns and there are no clinical distinctions between patients
with and without a family history. Other factors such as non-paternity, small family size,
incomplete penetrance, and incomplete family history can make familial cases appear to be
sporadic (SALS). The heritability of SALS is estimated to be 61% in a twin study23, but
estimates were much lower (12-21%) in genome-wide association studies (GWAS). 24,25

1.2 Genetics of familial ALS
1.2.1 SOD1
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The first genetic cause of ALS to be discovered was the Cu/Zn superoxide dismutase
SOD1. Linkage to the chr21q region was shown in ALS families26,27 where the causative gene
was later discovered to be SOD1 with 11 different mutations identified in 13 families28. There
are now 175 distinct mutations in SOD1 that have been submitted to the ALS mutation database
ALSoD29 (http://alsod.iop.kcl.ac.uk/). These mutations are distributed across the entire gene,
including some codons that have many different variants. For instance, six different mutation of
the glycine at amino acid position 94 have been reported (p.G94A, p.G94S, p.G94V, p.G94R,
p.G94D, p.G94C).
All reported mutations in SOD1 are dominant or dominant with reduced penetrance with
the exception p.D91A which is recessive30 or compound heterozygous with p.D96N.31 Multiple
studies have identified heterozygous p.D91A mutations as well32,33 suggesting that the mutation
can act in a dominant fashion as well. A proposed mechanism was that all recessive p.D91A
mutations share a cis-acting protective factor that is absent from dominant p.D91A
mutations.34,35
Mutations in SOD1 account for roughly 20% of FALS cases and 2% of SALS. Estimate
of SOD1 contribution to FALS in different populations ranged from 1.8% in the Netherlands to
50% in Scotland (only including studies with 10 or more subjects).36 One study in an Irish
population found no mutations in SOD1.37 In SALS populations, SOD1 accounted for 0-11.3%
of cases.36 In the United States, 23.4% of FALS cases had mutations in SOD138. There were no
studies in the US looking specifically at the contribution of SOD1 in SALS, but analyses of
mixed SALS/FALS cohorts showed SOD1 mutations in around 7.5% overall.39,40
The protein product of the SOD1 gene is responsible for converting toxic superoxide
anions, a byproduct of oxidative phosphorylation, to hydrogen peroxide. SOD1 protein is
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ubiquitously expressed and is predominantly located in the cytoplasm. Mutations in SOD1 result
in protein mis-folding and aggregations.41,42 The cellular effects of mutant SOD1 are widespread
including dysregulation of autophagy43, ER stress44, impaired axonal transport45, and disruption
of mitochondrial function.46

1.2.2 TARDBP and FUS
TAR DNA-binding protein (TARDBP) and fused-in sarcoma/translated in liposarcoma
(FUS/TLS or FUS) each account for about 4% of FALS and 1% of SALS.47 Both proteins are
structurally similar; they each possess a nuclear localization signal (NLS), glycine-rich domains,
RNA-repeat binding motifs (RRMs) and prion-like domains. Both TDP-43 (the protein product
of TARDBP) and FUS can bind to DNA and RNA and are involved in RNA transcription,
splicing, and transport.48 TDP-43 and FUS are normally located in the nucleus but can also
translocate to the cytoplasm. Ubiquitinated TDP-43 and FUS are found in cytoplasmic inclusions
in ALS patients.48
TARDBP was first selected as a candidate due to the presence of TDP-43 in cytoplasmic
inclusions in ALS patients.49 Sequencing of the gene in patients identified p.A315T50, and six
additional variants51 as a pathogenic mutations. A total of 52 mutations in TARDBP have been
reported in ALSoD, most of which lie in the C-terminal glycine-rich domain. The C-terminal
domain interacts with heterogeneous nuclear ribonucleoproteins (hnRNP) to modulate
alternative-splicing of mRNA transcripts.52
Mutations in FUS were first discovered in families with linkage53 or loss of
heterozygosity54 on chromosome 16. There are currently 79 FUS mutations listed in ALSoD.
These mutations are predominantly located in either the C-terminal NLS or in the glycine-rich
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domain.55,56 Mutations in the C-terminal domain were shown to prevent FUS from entering the
nucleus resulting in the formation of cytoplasmic aggregates.57

1.2.3 C9ORF72
Linkage to the chromosome 9p.21 region was first shown in 2006 in a large Scandinavian
family58. Additional linkage studies in Dutch59, Australian60, French61, Belgian62, Welsh63, North
American64, and French Canadian65 families identified the same locus. Genome-wide
association studies in sporadic ALS subjects showed association with the same region66,67,
however none of these groups were able to identify causative gene. The underlying cause of
chromosome 9p.21 ALS wasn’t discovered until 2011 when DeJesus Hernazdez et al.68 and
Renton et al.69 both identified a hexanucleotide (GGGGCC) repeat expansion in a non-coding
region of C9ORF72 (Figure 1.1).

Figure 1.1 The C9ORF72 gene and its three transcript variants. The gene has two alternate 5'UTR exons (1a and 1b).
Transcript 1 uses exon 1b and the expansion lies in the upstream promoter region. Transcript variants 2 and 3 use
exon 1a and the repeat is in the intron between exon 1b and exon 2.

Non-pathogenic alleles of the C9ORF72 repeat are most commonly 2 repeats with a
maximum around 25 repeats.68,70,71 The pathogenic size of repeat expansions is still being
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determined, but there is a clear distinction between expanded and unexpanded alleles as
determined by repeat-primed PCR (RP-PCR). Southern blots must be used to size expansions
larger than 30 repeats and show expansions of roughly 400-8000 repeats.68,72,73 Expansions in the
intermediate range of larger than 20 repeats but smaller than full expansions are seen as well, but
their role in pathogenesis is unclear.72,74–76
Full repeat expansions are found in 40% of FALS and 7% of SALS cases world-wide.77
Prevalence of the repeat expansion varies greatly by population with the highest rates in the
Finnish population (21% of SALS)69,77 and lowest rates in Asian populations (0-1.5% of SALS
in Japan, China, Korea, and Taiwan).77–83 In the United States, the C9ORF72 repeat expansion
accounts for about 36% of FALS and 6% of SALS.77 Full expansions are rare in control
populations. Most studies do not find any full expansions in neurologically normal controls
however a few have found expansions in a very small number of samples (0.15%-0.4%).69,72,77
The pathogenic mechanism of C9ORF72 repeat expansion is still not fully understood,
but is possibly a combination of RNA toxicity68,84–86, loss of C9ORF72 function68, formation of
G-quadruplex structures87–89 and aggregation of di-peptide repeats produced through repeatassociated non-ATG initiated (RAN) translation.90–92 It is unclear if the toxic effects of RNA foci
and di-peptide aggregates are due to the aggregates themselves or the sequestrations of RNAbinding proteins93,94 and proteins of the ubiquitin-proteasome pathway95,96, preventing them from
carrying out their normal functions. The normal function of C9ORF72 protein is not fully
known, but it shares structural similarities with the DENN family of proteins involved in
endosomal trafficking.97,98

1.2.4 Less common ALS genes
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Mutations in over 15 other genes have been identified in ALS, each of which is the cause
of less than 1% of ALS cases. The evidence regarding the role of these genes in summarized in
table 1.1. The number of mutations reported in ALSoD is included in this table, however it is
important to note that this database contains user submitted mutations, some of which are not
functional (including intronic and synonymous variants and variants found in controls) and not
all mutations that have been identified are submitted. With the exceptions of UBQLN2, SETX
and ALS2, mutations in all of these genes were identified in typical adult onset ALS. Mutations
in SETX were originally found in juvenile-onset ALS99 but are also found in adult-onset
cases.37,100,101 ALS2 was also identified in juvenile-onset ALS102,103, however no association has
been found between ALS2 and typical ALS.104
Table 1.1 Additional genes that cause ALS.

Gene

OPTN

ANG

Discovery Method

Protein function

Homozygosity
mapping105

Mediation of
apoptosis through
TNFα/NFκB
pathway106,
maintenance of Golgi
complex/ vesicle
trafficking107,
ubiquitin binding

Association,
candidate gene110–
112

DAO

DCTN1

Ribonuclease,
ribosomal RNA
synthesis113

Evidence
Missense mutations
results in neuronal cell
death through NFκB
pathway108, truncation
mutations unable to bind
ubiquitin105, autophagymediated degredation of
misfolded proteins
impaired109
Mutations result in
decreased ribonuclease
activity and decreased
nuclear translocation114

# ALSoD
mutations

37

29

Linkage analysis115

D-amino-acid
oxidase, degredation
of NMDA receptor
agonist D-serine
which accumulates
with age

Mutation results in
reduced enzymatic
activity and increased
apoptosis115

2

Candidate gene116

Forms complex which
acts as motor for
transport along
microtubules

Disruption of
DCNT1/DNCHC1
complex inhibits axonal
transport in motor
neurons117

7

7

FIG4

Candidate gene 118

Phosphatase,
regulation of
membrane bound
signaling lipid
PI(3,5)P 2 119

EWSR1

Candidate gene 121

RNA binding protein,
same family as FUS

TAF15

Candidate
gene122,123

RNA binding protein,
same family as FUS

Linkage analysis99

DNA/RNA helicase,
involved in premRNA processing124
and DNA damage
response125

SETX

SQSTM1

Candidate gene

127

Ubiquitin binding128,
mediation of NFκB
signaling129

Mutations reduce FIG4
activity resulting in
enlarge vacuoles when
transfected in yeast118,
mutations cause
neurodegeneration in
mouse120
Mutations result in mislocalization from nucleus
to cytoplasm in cultured
cells.121
Mutations result in
cytoplasmic foci in culture
and patient spinal cord,
cause neurodegeneration
in fruit flies123
Mutation results in altered
gene expression126
Aggregates of protein
product p62 co-localized
with TARDBP and FUS
in ubiquitinated inclusions
is ALS patients130,
Zebrafish knockdown has
motor neuron
phenotype131
Mutations result in
aggregate formation and
neurodegenation in fruit
flies134 and induce
ubiquitinated inclusions in
mice135, mutations disrupts
UPR133

10

1

7

8

16

VAPB

Linkage analysis132

Vesicle-binding
protein, involved in
ER functions
including unfolded
protein response
(UPR)133

VCP

Linkage analysis,
exome
sequencing136

ATP-binding protein
involved in vesicle
transport, required for
transport of proteins
from ER to cytosol137

Transgenic mice have
progressive weakness and
ubiquitinated
inclusions.138

7

ALS2

Linkage
analysis102,103

Modulation of
endosome139

Interacts with SOD1140,
axonal degeneration in
mice141

27

Linkage analysis142

Binds to proteasome
and ubiquitinated
proteins, delivers
proteins marked for
degradation to
proteasome142,143

Present in ubiquitinated
inclusions in spinal cord
from ALS patients142,
mutations disrupt
hnRNPA1 binding144

6

UBQLN2

8

2

CHMP2B

Candidate gene145

Component of
Endosomal Sorting
Complex Required for
Transport III
(ESCRT-III),
involved in recycling
of cell surface
receptors146

PFN1

Exome
sequening148

Regulation of actin
dynamics149

TUBA4A

Rare variant
burden analysis150

Microtubule subunit

MATR3

Exome
sequencing151

Nuclear matrix
protein involved in
mRNA processing152

hnRNPA1,
hnRNPA2B1

Linkage analysis,
exome
sequencing153

ERBB4

Linkage analysis,
exome
sequencing155

RNA-binding protein
involved in RNA
processing and
shuttling between
nucleus and
cytoplasm154
Epidermal growth
factor family of
receptor tyrosine
kinases, stimulated by
neuregulin and
involved in synaptic
plasticity156

Mutations result in
downregulation of genes
involved in axonal
transport and translation
initiation factors,
inhibition of autophagy147
Mutations result in
insoluble ubiquitinated
aggregates and inhibit
axon growth148
Mutations result in
aggregates and destabilization of
microtubule networks150
Mutations result in altered
cellular distribution,
shown to interact with
TDP-43151
Interact with TDP-4352,
mutations promote
formation of fibrils,
enhance recruitment of
hnRNPA1, hnRNPA2 to
stress granules153
Expressed in motor
neurons in rats157, knockout mice have defects in
motor neuron
development158

6

4

12

4

2

2

1.3 Genetics of sporadic ALS
1.3.1 Known FALS genes in SALS
As previously stated, the heritability of SALS is as high as 61%23, meaning there is still a
significant genetic component to sporadic disease. Mutations in many of the genes described
above have been identified in SALS as well as in familial forms.37,159–161 The majority of these
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studies have focused only on the most commonly involved genes (C9ORF72, SOD1, TARDBP,
and FUS) and the extent to which additional FALS genes cause SALS is relatively unexplored.
It is possible that mutations that have been found in SALS in Mendelian ALS genes are
not fully penetrant and require additional genetic and environmental factors to cause disease. The
idea of oligogenic inheritance, where mutations in more than one ALS gene are needed for
disease to develop, has recently been investigated as a mechanism for sporadic ALS.37,159,161 It
has also been proposed that ALS is a multistep process requiring an average of 6 different steps
or processes involved in disease development.162
Another possibility is that mutations may arise de novo in sporadic ALS patients. Denovo mutations have been reported in in both adult and juvenile onset SALS cases FUS, 163–165
SOD1166, and ERBB4.155 Exome sequencing of SALS trios with unaffected parents identified de
novo mutations in the CREST(SS18L1) gene.167 Identification of de novo mutations can be
difficult because DNA from parents is often unavailable due to the late onset of disease.

1.3.2 Risk loci
In addition to the known FALS genes, intermediate length CAG repeat expansions in the
ATXN2 gene are associated with increased risk for sporadic ALS.168 Expansions larger than 34
repeats are the cause of Spinocerebellar Ataxia type 2 (OMIM 183090), but CAG tracts in the
intermediate range of 27-33 repeats were associated with SALS. A meta-analysis showed that the
optimal cutoff to distinguish between ALS and controls was actually 29.169
Several genome-wide association studies (GWAS) have been performed in attempts to
identify common genetic variants that increase the risk of sporadic ALS. The only consistently
replicated genome-wide associations are with C9ORF72 and UNC13A.66,67,170,171 Associations
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were identified in DDP6 in an Irish population,172 FGGY (FLJ10986) in a North American
population of European descent173, ITPR2 in the Netherlands174, and ELP3 in the UK.175 These
signals have all failed to replicate in additional studies.115–120 It is likely that this is due to genetic
heterogeneity and that the effects of these variants is population specific.
With the failure of GWAS to identify variants that explain a significant portion of SALS,
researchers have started investigating the role of rare variants in disease. Rare variants are more
likely to have a larger effect size than common variants and while each individual variant may
not contribute a significant amount to the heritability of disease, the cumulative effects of rare
variants across entire genes can be significant. Associations of rare variants in SALS have been
reported in the nicotinic acetylcholine receptors182,183 and in protein disulfide isomerase genes.184
A recent whole exome sequencing study identified an excess of variants in TBK1, which is
involved in phosphorylation of OPTN and SQSTM1.185

1.3.3 Genes that modify phenotype
Three genes have been identified that modify ALS phenotype. A genome-wide
association study showed that rs1541160 in KIFAP3 was significantly associated with survival
and reduced expression of KIFAP3.186 Other studies have failed to replicate this
association187,188, so additional study is required to determine the significance of this gene in
survival. The genome-wide susceptibility locus UNC13A was also found to be significantly
associated with survival in two independent studies.171,189 rs12608932 was the associated SNP in
both studies which was the same SNP that was significantly associated with disease
susceptibility. A morpholino screen of genes that rescued the motor neuron degeneration in
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zebrafish model of SOD1 identified EPHA4. Rare mutations in this gene were subsequently
identified in a handful of individuals with unusually long survival from ALS.190

1.3.4 Environmental risk factors
With around 60% of ALS being inherited genetically, up to 40% could be accounted for
by environmental causes. Many studies have investigated possible environmental exposures and
the risk of ALS, however these studies often have methodological issues. There are hundreds of
possible environmental factors to investigate and the importance of the timing during
development of such exposures is unknown Some commonly studied factors include smoking,
physical fitness, heavy metals, pesticides, service in the armed forces, and occupations.191,192
These studies have produced conflicting results with some smoking studies, for instance,
showing increased risk, some showing increased risk only in women, and some showing no
increased risk.191 High levels of physical fitness have also been reported as a risk factor for ALS
with varying results depending on the measurement of physical fitness (i.e. prevalence of ALS in
former varsity athletes193 or population studies of occupational vs. leisure activity194). It was
proposed that the increase in ALS risk with leisure activity but not with occupational activity
means that an active lifestyle rather than fitness level is a risk factor.194 Meta-analyses will is
difficult or impossible due to differences in measurements of risk factors and outcomes between
studies. It is also likely environmental risk factors are dependent upon genetic background,
diluting our ability to identify relevant exposures. Increasing our understanding of the underlying
genetics of the disease will allow us to determine biologically plausible environmental risk
factors to perform a more directed analysis.

1.4 Neuroinflammation
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The identification of genes that cause ALS has shed light on many of the pathogenic
mechanisms of neurodegeneration, but pathological features of disease can provide us with
candidate genes for novel variant detection. The inflammatory response in the nervous system is
as important component of neurodegeneration195 yet no mutations in genes that regulate this
response have been identified in ALS patients. Microglia are the main immune cells of the CNS
and have a vital role in ALS. Mice that express mutant SOD1 only in the motor neurons have
delayed or no neurodegeneration compared to mice with ubiquitous mutant SOD1 expression.196–
198

Activated microglia are detected in sites of motor neuron injury in the motor cortex and

spinal cord of ALS patients.195,199,200
In addition to responding to pathogens, microglia are required for clearance of cellular
debris including injured neurons. Microglia have two different activation states: M1 which is
cytotoxic and M2 which can be protective. It is unclear whether dysregulated microglial
activation in ALS is detrimental due to a loss of the neuroprotective effects of removal of cellular
debris or an over-activation of the cytotoxic effects resulting in damage to healthy neurons.
There is evidence that microglia start in the neuroprotective state and transition to a neurotoxic
state as disease progresses.201 Genes that are involved in the mediation of microglial activity are
excellent candidates for identification of variants that increase the risk of ALS.

1.5 Summary
Previous genetic studies in ALS have been vital to our understanding of disease
pathogenesis. The genes that have been identified in families with ALS implicate several
important pathways including oxidative stress, RNA processing, protein misfolding and
aggregation, and inability to remove proteins targeted for degradation. Identification of novel
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genetic causes of disease can help us find new pathways and can also refine our understanding of
the pathways we already know.
Of particular interest is mechanism of the C9ORF72 repeat expansion which is the most
common cause of familial and sporadic ALS. There are several pathologic features associated
with the repeat expansion, but it is unknown which ones are the driving force behind
pathogenesis and which ones are byproducts of defects in other pathways. Understanding what
characteristics of the repeat effect disease presentation (i.e. expansion size, somatic instability,
and cis-acting modifiers) could give us clues about how they are causing ALS.
A higher than expected portion of SALS is caused by the hexanucleotide expansion in
C9ORF72 despite the fact that this mutation is also the most common cause of familial ALS. It is
presently unclear if these sporadic C9ORF72 cases are due to incomplete penetrance of the
expansion and small family sizes, or if they are de novo expansions. The expansions are known
to be unstable, therefore an asymptomatic “pre-expansion” carrier could pass on a pathogenic
expansion. Distinguishing between these mechanisms of inheritance will be important to our
understanding of how expansions cause disease.
Based on heritability studies in sporadic ALS, there is still a large genetic component of
SALS that has yet to be discovered. The higher heritability estimates from twin studies compared
to GWAS suggests that rare variants, which are not captured by GWAS play a significant role.
Mutations in genes that cause FALS have also been found in sporadic ALS, but they do not
account for a large portion of disease. The possibility of oligogenic inheritance in sporadic ALS
has been supported by a few studies. Identification of additional cases with mutations in multiple
ALS genes might reveal patterns in genes that are commonly mutated together which could
isolate pathways that work together in neurodegeneration.
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Chapter 2
Clinical characterization of a North American ALS cohort
2.1 Abstract
ALS is a clinically heterogeneous disease with variant in age of onset, site of symptom
onset, survival, and rate of progression. Understanding the factors that lead to variation in the
disease phenotype, for instance factors that lead to onset at a younger age or decrease survival
time, is important for understanding disease pathogenesis. It is also valuable information for
designing clinical trials in determining which demographic variables should be taken into
account for patient stratification and which variables to control for in determining treatment
outcomes. We analyzed the clinical characteristics of our ALS cohort and found that gender was
a significant predictor of site of onset with women more likely to have bulbar onset. Site of onset
was the most significant predictor of age of onset and subjects with bulbar onset had later age of
onset. Age of onset was the most significant predictor of both rate of progression and survival. A
younger age of onset was associated with slower progression and longer survival. Site of onset
was also significant to progression, as those with bulbar onset had more rapid progression than
those with limb onset. It will be important to take factors in consideration when analyzing the
impact of genetic and environmental factors in disease and in evaluation of treatment options.

2.2 Introduction
Amyotrophic lateral sclerosis is a universally fatal neurodegenerative disease. Onset
typically occurs in mid-to late life with age of onset typically ranging from 40-70 with an
average in the mid-60s.1–6 Death occurs within 3-5 years generally due to respiratory failure.7–11
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There is no cure for the disease and the only treatment available, Riluzole, only extends survival
by 2-3 months.12
Understanding the clinical characteristics and what influences them will not only aid in
patient counseling, but can provide insight into pathogenesis. Furthermore, knowing which
factors influence clinical aspects such as age of onset, survival, and progression will be crucial in
evaluation of novel therapies as they move to clinical trials. To delineate the clinical
characteristics of our ALS cohort, we looked at the relationships between family history, gender,
ethnicity, and site of onset, age of onset, survival, and progression.

2.3 Methods
2.3.1 Subjects
The work presented here includes a total of 873 subjects collected by the Washington
University Neuromuscular Genetics Project. Contributing sites included the Neuromuscular
Disease Center in St. Louis, Missouri (WUSM), the Virginia Mason Medical Center (VMMC),
Houston Methodist Hospital, University of Utah, and Cedars Sinai Medical Center. Subjects
from the Neuromuscular Genetics Projects were utilized for different studies included in this
work, including poooled-sample sequencing (n=391), exome sequencing (n=724), TREM2
(n=522), C9ORF72 discovery (n= 389), and C9ORF72 haplotype analysis (n=101). Most of the
subjects were included in multiple studies. Only subjects that were diagnosed with definite or
probable ALS according to El Escorial criteria were included in the analysis of clinical
characteristics (n=778).
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2.3.2 Data analysis
All analysis was performed in R version 3.1.1. Fisher’s exact tests were used to compare
categorical variables (gender, family history, site of onset, C9ORF72 status, ethnicity and
progression). Wilcoxon rank-sum tests were used to compare age of onset. Survival analysis was
performed using a multivariate Cox propotional hazards model with family history, gender, site
of onset, ethnicity, C9ORF72 status, and age of onset as covariates. Kaplan Meier curves were
generated for variables that were significantly associated with survival in the Cox proportional
hazard model. Age of onset was divided into quartiles for graphing (<50 years, 50-60 years, 6068 years, and >68 years). Spearman’s correlation was used to assess the relationship between
progression and age of onset.

2.4 Results
2.4.1 General characteristics
Clinical characteristics the 778 subjects diagnoses with definite or probable ALS are
summarized in table 2.1. Age of onset and survival were within previously reported ranges.
Here, survival was calculated for subjects who were deceased only. The male to female ratio was
1.3, which was also typical.13,14 Our cohort was predominantly of white, non-Hispanic origin.
The rate of family history and C9ORF72 repeat expansions in this cohort are not representative
of the ALS population as a whole since some sub-cohorts were ascertained based on either the
presence or absence of these characteristics. C9ORF72 was the only genetic factor we were able
to include since mutations in other genes are not common enough to perform analysis.
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Table 2.1 Clinical characteristics of 778 ALS patients.

% FALS (n=497)
39.2%
% C9ORF72 positive (n=773)
8.92%
% Male (n=778)
56.56%
Ethnicity (n=761)
White (non-Hispanic) 691 (91%)
African American 21 (2.8%)
Hispanic 32 (4.2%)
Other
17 (2%)
Age of onset, yrs. (n=766, median; range) 60; 14-85.9
Site of onset (n=769)
Spinal 532 (69%)
Bulbar 213 (28%)
Respiratory 11 (1.4%)
FTD
6 (0.8%)
Diffuse
2 (0.3%)
Survival, mo. (n=295, median; range )* 30; 6-220

2.4.2 C9ORF72
There were a total of 69 expansion carriers. The C9ORF72 expansion is significantly
more common in subjects with a family history of disease. 44/65 expansion carriers had a family
history of disease compared to 151/429 non-expansion carriers (only including subjects for
which C9ORF72 status and family history were known). The expansion was also slightly more
common in females compared to males (38/69 expansion carriers and 407/704 non expansion
carriers were men (Table2.2)).
Table 2.2 Differences in C9ORF72 expansion rates by demographic categories.

Gender (%Male)
Ethnicity (%White, non-Hispanic)
Family History (%+)

Expanded
44.9%
95.6%
67.7%
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Not expanded
57.8%
90.3%
35%

p-value
0.04222
0.1889
1.077x10-6

2.4.3 Site of onset
To analyze site of onset, all subjects with non-spinal onset (bulbar, diffuse, FTD, and
respiratory) were combined into a single category (Table 2.3). Non-spinal onset was significantly
more common in females compared to males. Non-spinal onset was also more common in FALS
compared to SALS, but was not significant when the same analysis was performed in only nonC9 expansion carriers. There was a trend toward non-spinal onset in C9 expansion carriers, but
this was not statistically significant on its own.
Table 2.3 Differences in site of onset by demographic categories.

Family History
Family History (C9-)
C9ORF72
Male
White, non-Hispanic

Spinal
35.6%
32.3%
8.0%
60%
93.1%

Not Spinal
45.6%
39.5%
11.5%
48.5%
89.8%

P-value
0.04282
0.1729
0.1338
0.003557
0.1095

Table 2.4 shows the site of first limb affected for subjects with spinal onset. There were 3
individuals whose onset was listed as “spinal” with no further information, and 2 with initial
symptoms in the trunk that are not listed in this table. The most common site of onset was in the
right upper limb and overall, upper limb onset was more common than lower limb. It was not
uncommon for subjects to have symptoms begin in both right and left limbs simultaneously, but
only 2 subjects had symptoms begin in both upper and lower limbs simultaneously. Women were
significantly more likely to have lower limb onset with 60% of women having lower limb onset
compared to 38% of men (p=1.319x10-6).
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Table 2.4 Site of initial symptoms in cases with spinal onset.

Upper
Lower
Both
Unspecified
Total

Left
80
76
1
0
157

Right
100
69
0
0
169

Both
31
38
1
0
70

Unspecified
64
64
0
3
131

Total
275
247
2
3
527

Within subjects with spinal onset, upper vs lower limb and right vs left limb had no effect
on age of onset, progression, or survival (data not shown). Progression rate was however
significantly associated with onset in left and right limbs simultaneously compared to onset in
either a left or right limb (p=0.007399). There was a higher prevalence of rapid progression, but
also a higher prevalence of very slow progression in those with both right and left onset (Figure
2.1).

Progression by Left/Right onset
0.6

Proportion

0.4

Left/Right
Both
Single

0.2

0.0
1

2

3

4

5

Progression Category

Figure 2.1 Progression rate in patients with either left or right or left and right limb onset.
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2.4.4 Age of Onset
Age of onset significantly differed for all categories tested (gender, family history,
C9ORF72 expansion status, ethnicity, and site of onset) except for C9ORF72 expansion status
(Figure 2.2). Interestingly, there was a significantly earlier onset in FALS subjects compared to
SALS; however the difference was due mostly to the higher proportion of C9ORF72 expansion
carriers in the FALS cohort, despite the fact that there was no significant association with
C9ORF72 status alone (Figure 2.2 A, B, C). The later onset in females compared to males was
due to the later onset in non-spinal onset, which is more common in females (Figure 2.2 D, E, F).
We also observed later onset in white, non-Hispanic subjects compared to other ethnicities
(Figure2.2 G).
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Figure 2.2 Age of onset by A. Family history of ALS, B. C9ORF72 expansion status, C. Family history stratified by
C9ORF72 status, D. Gender, E. Site of onset, F. Gender stratified by site of onset, and G. Ethnicity. The median is age of
onset in years is shown on the boxplots.
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Figure 2.2 continued.

2.4.5 Progression
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Progression rates were available for 637 subjects. However, rates were derived from three
different metrics. Subjects that had ALSFRS measured at multiple time-points were calculated as
change in ALSFRS/time between visits (in months). When this was unavailable, progression was
calculated for subjects who were deceased as 48/duration in months. Subjects collected at
VMCC were assigned to categories slow, typical-slow, typical, typical-fast, and fast based on
expert evaluation. In order to combine these data, ALSFRS/time and 48/duration were assigned
to categories 1 (slow), 2(typical-slow), 3 (typical), 4 (typical-fast), and 5 (fast) based on
percentile of their respective distributions such that the up to 10% = 1, 10-20% = 2, 20-80% = 3,
80-90% = 4, and 90-100% = category 5. The distribution of the proportion of subjects falling
into each category was roughly the same for all methods of calculation (Figure 2.3).

60%

Proportion

40%

Method
48/duration
ALSFRS
expert

20%

0%

1

2

3

4

5

Progression

Figure 2.3 Proportion of subjects falling into each progression category stratified by method of calculating progression.
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The distribution of progression categories differed between C9ORF72 expansion carriers
and non- expansion carriers (p=0.03057). C9ORf72 carriers had a higher proportion with typical
progression (category 3), while non-expansion carriers had more with slower progression
(category 1 and 2). Expansion carriers also had a higher proportion of rapid progression
(category 5) (Figure 2.4 A). There was also a significant difference between males and females
(p=0.008689). Females appeared to have a higher proportion of category 3 compared to males,
however males had a higher proportion in both categories 2 and 5 (Figure 2.4 B). There was a
clear association between site of onset and progression (p=0.003356) with a higher proportion of
cases with non-spinal onset in categories 4 and 5 (more rapid progression) and more cases with
spinal onset in categories 1 and 2 (slower progression) (Figure 2.4 C). We observed no
associations with family history or ethnicity (Figure 2.4 D, E).

Figure 2.4 Proportion of subjects falling into each progression category stratified by A. Gender, B. Family history of ALS, C.
C9ORF72 expansion status, D. Ethnicity, and E. Site of onset.
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Figure 2.4 continued.

There was a significant correlation between age of onset and progression (p=3.92x10-4,
spearman’s rho=0.14) with more rapid progression in subjects with later onset (median age of
onset for category1: 54yrs, category2: 60yrs, category3: 63.65yrs, category4: 61yrs).
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The relationship between progression and survival was not assessed since survival time was used
to calculate progression for many of the cases. Furthermore, there was no survival data for those
whose progression was determined by expert analysis.

2.4.6 Survival
The median survival time for subjects with known disease duration (due to documented
death) was 30 months. Using a Kaplan Meier survival analysis including all subjects (Figure
2.5), the median survival was estimated to be 42 (95% CI: 39-46).

0.8
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Kaplan Meier survival curve
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200
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Months after Onset

Figure 2.5 Kaplan Meier Survival curve of whole ALS cohort. Dotted lines represent 95% confidence interval.

We fit a multivariate Cox proportional hazards model to determine which variables
significantly impacted survival times (Table 2.5). Age of onset was the most statistically
significant predictor of survival time with earlier age of onset resulting in longer survival (Figure
2.6 A). C9ORf72 expansions also significantly impacted the probability of death with a hazard
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ratio over 2 meaning death was greater than twice as likely for expansion carriers compared to
non-expansion carriers (Figure 2.6 B). Spinal onset was significantly associated with longer
survival (Figure 2.6 C); however we have also shown that subjects with non-spinal onset have a
later age of onset. Therefore, when age of onset is included in the multivariate model, the p-value
is barely significant. Ethnicity was also significant in this model with longer survival in nonwhite subjects, (Figure 2.6 D).
Table 2.5 Cox-proportional hazards model. Median survival is calculated from Kaplan Meier curves

Variable
Family History
Male
C9ORF72 (+)
Spinal Onset
White, not Hispanic
Age of onset

Median Survival
Yes
No
41
48
48
39
32
43
48
30
41
NA
---
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Hazard Ratio
1.062
0.785
2.159
0.742
2.252
1.039

P-value
0.69
0.09
1.6x10-5
0.05
0.037
4x10-10

Figure 2.6 Kaplan Meier survival curves stratified by A. Age of onset, B. C9ORF72 expansion status, C. Site of onset, and D.
Ethnicity.

2.5 Discussion
Here we have provided an analysis of the some of the clinical characteristics of
amyotrophic lateral sclerosis in a North American cohort. The patients included in this analysis
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were derived from multiple centers and were included in a variety of genetic studies described in
subsequent chapters. There is some amount of ascertainment bias for certain characteristics. For
instance, family history of ALS is more likely to be recorded when it is positive, but is left blank
rather than recorded as “sporadic” otherwise. This artificially inflates the rate of FALS in our
cohort, but should not affect the relationship between family history and clinical presentation.
We initially found bulbar onset to be more common in cases with a family history of
ALS, however there was no difference in site of onset when we stratified for C9ORF72 status
despite the fact that there was not a significant difference in site of onset between expansion
carriers and non-expansion carriers. This is consistent with our previously reported finding that
bulbar onset is more common in expansion carriers with FALS but not in expansion carriers with
SALS.15 Gender was the only characteristic that had a significant association with site of onset
with women more likely to have bulbar onset than men, an association that is well known.13,14,16–
19

Further stratifying spinal onset by limb showed that women with spinal onset were more likely

to have lower limb onset than men. To our knowledge, this association has not been previously
reported.
Site of onset was the factor most significantly associated with age of onset with subjects
with spinal onset having earlier onset than those with bulbar and other onset. While it appeared
that onset was later in women, this effect was due to the increase in bulbar onset in women
compared to men. Similarly, the later onset we observed in familial cases was due to the increase
in bulbar onset in FALS expansion carriers. We also noted that the age of onset was earlier in
non-White subjects.
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We found age of onset to be the most important indicator of survival as other studies have
also shown (reviewed by Chiò et al.7).We also noted that C9ORF72 expansions were
significantly associated with shorter survival time. Ethnicity and site of onset were associated
with survival, although less so, even when controlling for age of onset. Studies have consistently
shown shorter survival times in bulbar onset.20–26 The studies investigating the role of ethnicity
in survival times have conflicting results however most have shown no difference in survival
times between ethnicities.8,10,27 It is possible that the association we see is due to the low
numbers of non-white subjects, but differences in follow-up play a role as well. Obituaries are
often used to determine survival since many patients don’t return to the same clinic and nonwhite patients are less likely to have obituaries published, resulting in more censored data.
Progression rate was significantly associated with both age and site of onset which was
consistent with the association with survival. In addition to more rapid progression in patients
with bulbar onset, we also showed that within subjects with spinal onset, there progression was
more rapid in when symptoms began in right and left limbs simultaneously. We also saw an
association with C9ORF72 with non-expansion carriers having higher numbers of slower
progression, however there were also more non-expansion carriers in the most rapid category.
This is possibly caused by specific mutations in other genes, such as SOD1, that are associated
with rapid progression, however we did not include mutations other than the C9ORF72
expansion in this analysis. We did not examine the relationship between progression and survival
since survival time was used to calculate progression rate in many cases.
There were other clinical characteristics, such as frontotemporal dementia, and used of
Riluzole we did not include in analysis due to differences in data collection. Patients in this
cohort were collected from four different centers, all of which collected different information.
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We noted that cognitive changes were not always recorded and assessment methods were not
consistent. While this analysis is not completely comprehensive, we did find several significant
associations that need to be taken into account in further analysis.

48

2.6 References
1. Testa, D., Lovati, R., Ferrarini, M., Salmoiraghi, F. & Filippini, G. Survival of 793 patients
with amyotrophic lateral sclerosis diagnosed over a 28-year period. Amyotroph. Lateral
Scler. Other Motor Neuron Disord. 5, 208–212 (2004).
2. Logroscino, G. et al. Incidence of amyotrophic lateral sclerosis in Europe. J. Neurol.
Neurosurg. Psychiatr. 81, 385–390 (2010).
3. Huisman, M. H. B. et al. Population based epidemiology of amyotrophic lateral sclerosis
using capture-recapture methodology. J. Neurol. Neurosurg. Psychiatr. 82, 1165–1170
(2011).
4. Uenal, H. et al. Incidence and geographical variation of amyotrophic lateral sclerosis (ALS)
in Southern Germany--completeness of the ALS registry Swabia. PLoS ONE 9, e93932
(2014).
5. Piemonte and Valle d’Aosta Register for Amyotrophic Lateral Sclerosis (PARALS).
Incidence of ALS in Italy: evidence for a uniform frequency in Western countries.
Neurology 56, 239–244 (2001).
6. Fang, F. et al. Amyotrophic lateral sclerosis in Sweden, 1991-2005. Arch. Neurol. 66, 515–
519 (2009).
7. Chiò, A. et al. Prognostic factors in ALS: A critical review. Amyotrophic Lateral Sclerosis
10, 310–323 (2009).
8. Del Aguila, M. A., Longstreth, W. T., McGuire, V., Koepsell, T. D. & van Belle, G.
Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology 60, 813–819
(2003).
9. Jordan, H., Fagliano, J., Rechtman, L., Lefkowitz, D. & Kaye, W. Population-based
surveillance of amyotrophic lateral sclerosis in New Jersey, 2009-2011. Neuroepidemiology
43, 49–56 (2014).
10. Jordan, H., Fagliano, J., Rechtman, L., Lefkowitz, D. & Kaye, W. Effects of demographic
factors on survival time after a diagnosis of amyotrophic lateral sclerosis.
Neuroepidemiology 44, 114–120 (2015).
11. Amyotrophic lateral sclerosis. (Taylor & Francis, 2006).
12. Miller, R. G., Mitchell, J. D. & Moore, D. H. Riluzole for amyotrophic lateral sclerosis
(ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 3, CD001447 (2012).
13. Manjaly, Z. R. et al. The sex ratio in amyotrophic lateral sclerosis: A population based study.
Amyotroph Lateral Scler 11, 439–442 (2010).

49

14. McCombe, P. A. & Henderson, R. D. Effects of gender in amyotrophic lateral sclerosis.
Gend Med 7, 557–570 (2010).
15. Harms, M. B. et al. Lack of C9ORF72 coding mutations supports a gain of function for
repeat expansions in amyotrophic lateral sclerosis. Neurobiol. Aging 34, 2234.e13–19
(2013).
16. Atsuta, N. et al. Age at onset influences on wide-ranged clinical features of sporadic
amyotrophic lateral sclerosis. J. Neurol. Sci. 276, 163–169 (2009).
17. Traynor, B. J. et al. Incidence and prevalence of ALS in Ireland, 1995–1997 A populationbased study. Neurology 52, 504–504 (1999).
18. Nalini, A., Thennarasu, K., Gourie-Devi, M., Shenoy, S. & Kulshreshtha, D. Clinical
characteristics and survival pattern of 1153 patients with amyotrophic lateral sclerosis:
Experience over 30 years from India. Journal of the Neurological Sciences 272, 60–70
(2008).
19. The Scottish Motor Neuron Disease Register: a prospective study of adult onset motor
neuron disease in Scotland. Methodology, demography and clinical features of incident cases
in 1989. J. Neurol. Neurosurg. Psychiatr. 55, 536–541 (1992).
20. Traynor, B. J. et al. Clinical features of amyotrophic lateral sclerosis according to the El
Escorial and Airlie House diagnostic criteria: A population-based study. Arch. Neurol. 57,
1171–1176 (2000).
21. Scotton, W. J. et al. Prognostic categories for amyotrophic lateral sclerosis. Amyotroph
Lateral Scler 13, 502–508 (2012).
22. Chancellor, A. M. et al. The prognosis of adult-onset motor neuron disease: a prospective
study based on the Scottish Motor Neuron Disease Register. J. Neurol. 240, 339–346 (1993).
23. Forbes, R. B., Colville, S., Cran, G. W., Swingler, R. J. & Scottish Motor Neurone Disease
Register. Unexpected decline in survival from amyotrophic lateral sclerosis/motor neurone
disease. J. Neurol. Neurosurg. Psychiatr. 75, 1753–1755 (2004).
24. Lee, J. R., Annegers, J. F. & Appel, S. H. Prognosis of amyotrophic lateral sclerosis and the
effect of referral selection. J. Neurol. Sci. 132, 207–215 (1995).
25. Chiò, A. et al. Early symptom progression rate is related to ALS outcome: a prospective
population-based study. Neurology 59, 99–103 (2002).
26. Tysnes, O. B., Vollset, S. E. & Aarli, J. A. Epidemiology of amyotrophic lateral sclerosis in
Hordaland county, western Norway. Acta Neurol. Scand. 83, 280–285 (1991).
27. Gundogdu, B., Al-Lahham, T., Kadlubar, F., Spencer, H. & Rudnicki, S. A. Racial
differences in motor neuron disease. Amyotrophic Lateral Sclerosis and Frontotemporal
Degeneration 15, 114–118 (2013).

50

Chapter 3
Genetic Characterization of a North American ALS cohort
The work presented in this chapter resulted in the following publications
1. Amyotrophic lateral sclerosis onset is influenced by the burden of rare variants in known
amyotrophic lateral sclerosis genes. Cady J, Allred P, Bali T, Pestronk A, Goate A, Miller
TM, Mitra RD, Ravits J, Harms MB, Baloh RH.Ann Neurol. 2015 Jan;77(1):100-13
2. Lack of C9ORF72 coding mutations supports a gain of function for repeat expansions in
amyotrophic lateral sclerosis. Harms MB, Cady J, Zaidman C, Cooper P, Bali T, Allred
P, Cruchaga C, Baughn M, Libby RT, Pestronk A, Goate A, Ravits J, Baloh RH.
Neurobiol Aging. 2013 Sep;34(9):2234.e13-9

3.1 Abstract
To define the genetic landscape of amyotrophic lateral sclerosis (ALS) and assess the
contribution of possible oligogenic inheritance, we comprehensively analyzed 17 known ALS
genes in 391 ALS patients from the United States. Targeted pooled-sample sequencing was used
to identify variants in 16 ALS genes and repeat-primed PCR was used to detect expansions in
C9ORF72 and ATXN2. 64.3% of familial and 27.8% of sporadic subjects carried potentially
pathogenic novel or rare coding variants in the genes under investigation. 3.8% of subjects had
variants in more than one ALS gene, and these individuals had disease onset ten years earlier
(p=0.0046) than subjects with variants in a single gene. The number of potentially pathogenic
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coding variants did not influence disease duration or site of onset. The rates of subjects carrying
variants were significantly higher than previous reports using less comprehensive sequencing
approaches. A significant number of subjects carried variants in more than one gene, which
influenced the age of symptom onset and supports oligogenic inheritance as relevant to disease
pathogenesis.

3.2 Introduction
Amyotrophic lateral sclerosis (ALS) is caused by degeneration of upper and lower motor
neurons which results in progressive paralysis and ultimately death. As the most common motor
neuron disease, the incidence of ALS is 0.44-3.2/100,000 person years1 and data from the
National ALS Registry demonstrates a prevalence of 3.9/100,000 cases in the US.2 5-10% of
ALS patients have a family history of the disease (FALS)3–5 and the genetic analysis of these
FALS pedigrees has fueled the discovery of more than 20 ALS genes, some with highpenetrance and others with lower penetrance or tentative associations to disease (reviewed in
Harms and Baloh, Andersen and Al-Chalabi).6,7 Mutations in many of these genes are also
found in patients without a family history of ALS (sporadic ALS [SALS]), with high-penetrance
mutations found in ~10%.8–14 Recently, the heritability of SALS has been estimated to be 1221% from genome-wide association studies15,16 and as high as 61% in twin studies17 suggesting
additional genetic influences on ALS risk remain to be identified.
The emergence of next-generation sequencing techniques has driven down sequencing
costs and made it feasible for studies to abandon sequential candidate gene sequencing in favor
of analyzing larger numbers of genes simultaneously. One of the more powerful and costeffective sequencing techniques for screening moderate number of genes in medium sized
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cohorts is termed pooled-sample or pooled-DNA sequencing (Figure 3.1).18 In this method,
DNA samples from multiple patients are pooled prior to PCR amplification of target regions.
PCR products are then combined and sequenced en masse using short-read/next-generation
sequencing platforms.18 Analysis programs such as SPLINTER utilize statistical algorithms to
identify potential variants with high sensitivity, and are capable of detecting single alleles in
pools of up to 500 individuals.19 Pooled-sample sequencing therefore overcomes the resource
and time-intensive draw-backs of traditional Sanger sequencing approaches at a fraction of the
cost.18,19
As a result of next-generation sequencing advances, studies have begun addressing the
relative contributions of individual genes in ALS subjects with and without family histories,
revealing significant heterogeneity between populations.8–12,20 Furthermore, screening multiple
ALS genes in parallel has also uncovered a number of patients that carry potentially pathogenic
variants in more than one known ALS gene.12 The unexpected frequency of this phenomenon has
raised the hypothesis that some fraction of apparently sporadic ALS8,12 could be caused by the
co-occurrence of two or more genetic variants with additive or synergistic deleterious effects.
Each variant alone could be tolerated but when combined with a second variant would exceed
the threshold required for neurodegeneration. Although several papers have reported cases with
multiple variants in ALS genes, no effect on phenotype or disease manifestations has been
noted.9,12
We have used pooled-sample sequencing as the major technique to analyze 17 ALSassociated genes in 391 ALS subjects from a United States clinic-based cohort. In creating the
most comprehensively-sequenced North American ALS cohort to date, this study measures the
burden of rare and novel variants in known ALS genes and defines the frequency of potential
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oligogenic cases. Importantly, we demonstrate that subjects with rare or unique variants in more
than one ALS gene have earlier ages of disease onset.

3.3 Methods
3.3.1 Subjects
Between 2005 and 2011, patients diagnosed with ALS at the Washington University
Neuromuscular Disease Center in St. Louis, Missouri (WUSM) or at the Virginia Mason
Medical Center (VMMC) were systematically asked to participate in genetic studies. All
subjects provided informed and written consent for clinical-genetic correlation studies of ALS
that had been approved by institutional ethics review boards. At WUSM, subjects with or
without a family history of ALS were included, while only sporadic cases were enrolled at
VMMC. All subjects had been evaluated by neuromuscular specialists and diagnosed with
probable or definite ALS according to El Escorial criteria.21

A subset of included subjects

(mostly with FALS) also underwent sequencing for one or more ALS genes at commercial
reference laboratories, which identified 6 subjects with SOD1 or TARDBP mutations.

3.3.2 Genetic investigations
Sequencing of ALS-associated genes: All coding exons and 20 flanking bases of SOD1, FUS,
TARDBP, ANG, OPTN, VCP, VAPB, DAO, DCTN1, FIG4,SETX, TAF15, EWSR1, UBQLN2 ,
SQSTM1, and C9ORF72 were sequenced in our cohort using the pooled-sample method as
previously described in detail and schematized in Figure 1.18,22 Genomic DNA was extracted
from whole blood or saliva of individual subjects according to standard protocols. Double-
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stranded DNA was carefully quantified by fluorimetry based on SYBR gold fluorescence.
Pooled-sample gDNA pools were then created by combining equimolar amounts of DNA from
multiple individuals: two pools containing 21 samples each were used to validate the method,
while the remaining samples were divided into 8 pools of 30-50 samples each.

Figure 3.1 Schema of pooled-sample sequencing workflow

Primer pairs for all coding exons and at least 20bp of flanking sequence were designed
using Primer3 (http://biotools.umassmed.edu/bioapps/primer3_www.cgi) and the RefSeq gene
annotations found in GRCh37/hg19 (accession numbers NM_000454.4, NM_004960.3,
NM_007375.3, NM_001145.4, NM_001008211.1, NM_007126.3, NM_004738.4,
NM_001917.4, NM_004082.4, NM_014845.5, NM_015046.5, NM_139215.1, NM_013986.3,
NM_013444.3, NM_003900.4, and NM_001256054). Primer sequences are available upon
request. Amplicons from each pool were sequenced on one lane of HiSeq2000 (Illumina), with
single-end 42bp reads. UBQLN2, SQSTM1, and C9ORF72 were reported after initial sequencing
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was underway and all subjects were sequenced as part of 6 pools across two lanes of Illumina
HiSeq2000. Exon 1 of SQSTM1 was not sufficiently covered using pooled-sample methods and
required Sanger sequencing of each individual subject. Mutations in PFN1 were reported after
analysis was already underway so this gene was not assessed.23
Bioinformatic analysis: Sequence alignment and variant calling were performed using "short
indel prediction by large deviation inference and nonlinear true frequency estimation by
recursion" (SPLINTER).19 The SPLINTER program generates an error model based on the
negative control for each run. The error model is used to calculate a p-value for each SNP that is
detected. SPLINTER calculates the p-value cutoff that has the highest sensitivity and specificity
to distinguish true variants in the positive control vector and uses the ratio of sequencing reads
with and without variant nucleotides to estimate the frequency of a given variant within a pool.
All variants called by SPLINTER were filtered for variants within exons or the 10
flanking bases and then visually inspected using Integrated Genomics Viewer(IGV)24,25 after
realignment to Hg19 using Novoalign (http://www.novocraft.com) and SAMtools.26 Variants
were annotated using SeattleSeq (http://sngs.washington.edu/SeattleSeqAnnotation131/), SIFT
(http://sift.jcvi.org/), MutationTaster (http://www.mutationtaster.org/), and PolyPhen2
(http://genetics.bwh.harvard.edu/pph2/). The effect of splice-site mutations was predicted by
Human Splicing Finder (http://www.umd.be/HSF). Population frequencies for each variant were
determined in dbSNP, the 1000 Genomes Project, and the NHLBI Exome Sequencing Project
version ESP6500 exome variant server (ESP6500)
(http://ESP6500.gs.washington.edu/ESP6500/ [1 Dec 2013]).
Variant validation and classification: Novel and rare (<1% MAF in ESP6500) nonsynonymous and splicing variants that passed visual inspection were genotyped in individual
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DNA samples by either Sequenom or Sanger sequencing to both validate the variant and
determine which subject(s) carry them. Validated variants were assigned to four categories
based on their presence in the ALS literature and frequencies in population databases. Category
1 variants have been previously reported in ALS patients but are absent from population
databases. Category 2 variants have been reported in ALS patients but are present in population
databases. Category 3 variants are novel (i.e. they have not been reported in ALS patients or
population databases). Category 4 variants have not been reported in ALS patients but are
present in population databases. Pathogenicity prediction algorithms were not utilized for
category assignments because of their poor track-record in predicting disease-causing
mutations.27,28 All four categories of variants were considered to be potentially pathogenic
mutations.
C9ORF72 repeat expansion detection: All subjects were also screened for C9ORF72 repeat
expansions using standard repeat-primed PCR.29 Identification of a decrementing saw-tooth
pattern with 6-bp periodicity and more than 30 peaks was considered positive for an expanded
repeat, as in previous applications of this assay. In practice, however, all samples considered
positive in this study showed more than 60 peaks.
ATXN2 repeat size: The CAG repeat region was amplified using primers 5’ FAM-CCC CGC
CCG GCG TGC GAG CCG GTG TAT G 3’ and 5’ CGG GCT TGC GGA CAT TGG 3’. PCR
was performed with PhusionHigh-Fidelity PCR Master Mix with HF Buffer (New England
BioLabs) with cycles as follows: 30 seconds 98°C, 35 cycles (10 seconds 98°C, 30 seconds
72°C), and 2 minutes 72°C. Repeat lengths were determined by fluorescent capillary gel
electrophoresis. While intermediate-length alleles were originally considered to be 27-33
repeats30, subsequent meta-analysis has shown 29 repeats to be the optimal cutoff to distinguish
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ALS subjects from controls.31 Therefore we considered repeat sizes of 29-33 to be of
intermediate length.

3.3.3 Statistical Analysis
Statistical tests comparing patient characteristics were performed in R v3.0.1. Wilcoxon
rank-sum tests were used to assess age of onset and survival, and Fisher’s exact tests were used
to analyze site of symptom onset, family history, gender, and ethnicity.
To identify rare and novel SNPs that might be over-represented in sporadic ALS subjects,
we used Fisher's exact tests to compare each candidate SNV’s allele frequency in sporadic ALS
versus controls. By genotyping variants across a range of frequencies, we found that SPLINTER
predicted frequencies and genotyped frequencies were highly correlated (r2=0.9596) as in prior
studies19 (data not shown). Therefore SPLINTER-predicted frequencies were used for ALS SNPs
that were not genotyped. We included only SALS samples with self-reported non-Hispanic
white backgrounds (n=309) and used subjects with European ancestry in ESP6500 and the 1000
Genomes Project (1000genomes.org)32 as our control population(n=4679). Variants were
selected for replication based on p-values and potential functional significance. Selected variants
were genotyped in 552 ALS cases and 464 neurologically normal controls from the Coriell DNA
repository. Tests were performed in R v3.0.1.
Gene-based tests comparing the burden of rare variants in cases compared to controls
were performed using SKAT-O.33 We included the same individuals as were used for singlevariant testing. Only missense and nonsense variants with MAF<0.1 in the control cohort were
included in analysis. We used a Bonferonni correction to account for multiple testing
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(α=0.0036). UBQLN2 was excluded from analysis since SKAT does not handle data from the Xchromosome.

3.4 Results
3.4.1 Subject Characteristics
Demographic and disease characteristics for the 391 sequenced subjects with ALS are
shown in Table 3.1. Age at onset, site of first symptom, and overall disease survival were
similar to other population-based and referral center-based cohorts (reviewed in Harms and
Baloh).6 42 subjects (10.7%) had a family history of ALS, which is comparable to other ALS
referral center-based cohorts.
Table 3.1 Subject demographics and disease characteristics. Data for aethnicity, bsite of onset, and cage at onset was missing for
14, 5, and 4 subjects respectively. dSurvival data was available for 172 subjects.

Total ALS cases

391

Subjects with family history of ALS

10.7%

Self-reported Caucasian (%)a

93.1%

Male sex (%)
Limb Onset (%)b

57%
69.2%

Age at Onset (mean, stdev)c

59.7±12.8

Age at Onset (median, range)

61,14-85

Survival in months (mean, stdev)d

41.3±27.7

Survival in months (median, range)

34, 7-147

3.4.2 Sequencing Results
In total, 152 PCR amplicons were required to amplify 203 exons of the 16 genes analyzed
by pooled-sample sequencing. Twelve lanes of next-generation sequencing yielded 1.2 billion

total reads (~3 million per subject) to produce a coverage depth exceeding 67x per allele for all
amplicons across all pools. Most amplicons showed considerably higher coverage (range: 67987, median=458.68, IQR=355.98-560.51).
Sensitivity for single alleles (i.e. heterozygous variants present in a single individual
within a given pool) was 98% (100% in 12 of 16 pools and 92% in the remainder), as determined
by the detection rate of positive control singleton variants. We also compared pooled-sample
results to whole-exome data for 35 subjects and found no missed variants in targeted genes.
Finally, we detected all six previously-found mutations with the correctly assigned singleton
frequencies.
To assess the false positive rate at the low allele frequencies in which we were interested,
we performed validation genotyping of 100 allele calls for 67 non-synonymous or splice-site
variants that were either rare (<1% minor allele frequency) or absent in population databases. 13
of 100 calls (8 SNPs, including 4 SNPs that were identified and validated in other pools) were
not validated by subsequent genotyping, resulting in a false-positive rate of 13%. The falsepositives included 5 calls that were true in other pools.
After filtering and validation, 67 rare or novel coding variants were identified (65 by pooledsample sequencing and two by direct sequencing of exon 1 of SQSTM1). Variants were
identified in all sequenced genes except for UBQLN2.

3.4.3 Variant Identification and Classification
Coverage of targeted bases was ≥130 fold for each subject. Sensitivity for detecting a
variant present as a single allele within the pool of normal alleles averaged 98% (100% in 12 of
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16 pools and 92% in the remainder). Based on validation genotyping, 13% of variants were
determined to be false-positives.
In total, we found 66 rare or novel coding or splice-site variants (Table 3.2). One-third of
these (n=23) were previously reported in ALS patients. Ten of these ALS-associated variants
were not found in population databases of genetic variation (Category 1) and review of the
literature showed that all of them are well-established causal mutations. The remainder of
variants previously reported in ALS (n=13) were found to be present in population databases
(Category 2). With the exception of SOD1 D91A (where causality is clear), these variants
lacked conclusive evidence of causation in the literature. Two-thirds (n=43) of variants we
identified have not been previously reported in ALS, including 17 that are absent from
population databases (Category 3) and 26 that are rare in population databases (Category 4).

61

c

Table 3.2 Novel and rare coding variants identified in ALS genes. Rare was considered a global minor allele frequency <1%. aGRCh37/hg19 bdbSNP138
cDNA location and predicted protein changes refer to isoforms listed in Methods. dAllele counts are listed as alternate alleles found/total alleles assayed. eFor all
but the ATXN2 and C9ORF72 repeats, global allele counts were calculated from all subjects in the 1000 Genomes and NHLBI Exome Sequencing Projects.
Global allele counts for C9ORF72 repeat expansions were derived from34 while intermediate CAG repeats in ATXN2 were derived from 30,31. fPopulation allele
count refers to the population most closely matching that of the ALS subjects(s) carrying the variant. Unless indicated by a symbol, this is European ancestry
(EA subjects from ESP6500 and 1000genomesEUR). Symbols used to denote other populations: †African American (AA subjects from
ESP6500+1000genomesAFR); ‡Hispanic (1000genomesAMR) §Asian (1000genomesASN). *indicates at least one subject carrying that specific variant also
carried another variant(s) in an analyzed ALS gene

Predicted
Gene
Name

Genomic
locationa

b

dbSNP ID

cDNA
changec

FALS

SALS

Globale

Populationf

1/84

11/698*

19/2982

19/2982

14/84*

21/698

11/7598

11/7598

12:112036785

rs193922927

C9ORF72

9:27573539

-

FUS

16:31202739

rs121909668

c.1561C>G

R521G

1/84

0/698

0/15190

0/9358

FUS

16:31202752

-

c.1574C>T

P525L

0/84*

1/698

0/15190

0/9358

-Reported in ALS

SOD1

21:33032096

rs121912442

c.14C>T

A5V

1/84*

1/698

0/15190

0/9358

-Not in databases

SOD1

21:33036142

rs121912431

c.112G>A

G38R

1/84*

0/698

0/15190

0/9358

SOD1

21:33038821

-

c.229G>T

D77Y

1/84

0/698

0/15190

0/9358

SOD1

21:33039600

-

c.269C>T

A90V

0/84

1/698

0/15190

0/9358

SOD1

21:33039672

rs121912441

c.341T>C

I114T

1/84

1/698

0/15190

0/9358

TARDBP

1:11082325

rs80356719

c.859G>A

G287S

0/84

1/698*

0/15190

0/9358

TARDBP

1:11082409

rs80356726

c.943G>A

A315T

1/84

0/698

0/15190

0/9358

VCP

9:35065360

rs121909329

c.464G>A

R155H

1/84

0/698

0/15190

0/9358

ANG

14:21161845

rs121909536

c.122A>T

K41I

0/84

1/698*

27/15190

23/9358

Category 1:

Category 2:
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Q188(29-33)

Allele Countsd

ATXN2
Expansions

c.532_534CAG

Predicted
protein
changec

ANG

14:21162130

rs121909543

c.407C>T

P136L

1/84*

0/698

1/15190

1/9358

-Reported in ALS

DCTN1

2:74588717

rs72466496

c.3746C>T

T1249I

2/84*

1/698*

44/15190

39/9358

-Rare in databases

DCTN1

2:74592252

rs72659383

c.3146G>A

R1049Q35

0/84

1/698*

22/15190

21/9358

FIG4

6:110036336

rs121908287

c.122T>C

I41T36

0/84

1/698

17/15190

16/9358

OPTN

10:13166053

rs142812715

c.941A>T

Q314L

0/84

1/698

3/15190

3/9358

SETX

9:135140020

rs151117904

c.7640T>C

I2547T

2/84

8(1hom)/698*

76/15190

71/9358

SETX

9:135202325

rs112089123

c.4660T>G

C1554G

0/84

6/698*

47/15190

40/9358

SOD1

21:33039603

rs80265967

c.272A>C

D91A

1/84

2(1hom)/698

9/15190

9/9358

SQSTM1

5:179248034

rs200396166

c.98T>T

A33V

0/84

2/698

6/15190

6/9358

SQSTM1

5:179251013

rs145056421

c.457G>A

V153I

1/84*

0/698

9/15190

9/9358

SQSTM1

5:179252184

rs11548633

c.712A>G

K238E

0/84

5/698*

41/15190

32/9358

TAF15

17:34171525

rs200175347

c.1222C>T

R408C

0/84*

1/698

2/15190

2/9358

DAO

12:109278977

-

c.194+1G>A

Splice donor

0/84

1/698

0/15190

0/9358

DCTN1

2:74588653

-

c.3810C>A

H1270Q

0/84

1/698*

0/15190

0/9358

-Not reported in ALS

DCTN1

2:74590527

-

c.3239C>T

S1080F

0/84

1/698

0/15190

0/4898†

-Not in databases

EWSR1

22:29682932

-

c.620C>G

T207S

0/84

1/698

0/15190

0/9358

FIG4

6:110087935

-

c.1588_1589delTT

F530Ter

0/84

1/698

0/15190

0/9358

FUS

16:31202282

-

c.1394-2delA

Splice site

1/84

0/698

0/15190

0/9358

OPTN

10:13160964

-

c.703C>T

Q235Ter

0/84

1/698

0/15190

0/9358

SETX

9:135202223

-

c.4762G>A

A1588T

0/84

1/698

0/15190

0/572§

SETX

9:135203632

-

c.3353C>A

T1118K

0/84

1/698

0/15190

0/9358

SETX

9:135206694

-

c.980A>T

E327V

0/84

1/698

0/15190

0/9358

Category 3:
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SETX

9:135210013

-

c.820A>G

M274V

0/84

1/698*

0/15190

0/9358

SETX

9:135211743

-

c.658A>C

K220Q

0/84

1/698

0/15190

0/9358

SETX

9:135211898

-

c.503G>A

R168Q

0/84

1/698*

0/15190

0/9358

SETX

9:135224775

-

c.41C>T

T14I

0/84

1/698

0/15190

0/9358

SOD1

21:33038791

-

c.199C>G

P67A

1/84*

0/698

0/15190

0/9358

SQSTM1

5:179248079

-

c.143T>T

L48P

0/84

1/698

0/15190

0/9358

TARDBP

1:11082589

-

c.1123A>G

S375G

0/84

1/698

0/15190

0/9358

ANG

14:21161973

rs17560

c.250A>G

K84E

0/84

1/698

70/15190

69/4898†

DAO

12:109294259

rs4262766

c.992G>A

G331E

0/84

1/698

4/15190

0/9358

-Not reported in ALS

DAO

12:109294301

rs143732132

c.1034C>T

S345F

1/84*

0/698

3/15190

3/9358

-Rare in databases

DCTN1

2:74593101

rs145130328

c.2805C>G

I935M

0/84

1/698

4/15190

0/362‡

DCTN1

2:74598723

rs55862001

c.586A>G

I196V

1/84

4/698*

77/15190

70/9358

DCTN1

2:74604801

rs374419252

c.332C>G

S111C

0/84

1/698

1/15190

0/9358

EWSR1

22:29682919

rs144503053

c.607T>A

S203T

0/84

1/698

1/15190

1/9358

FIG4

6:110081543

rs142463699

c.1228A>C

T410P

0/84

1/698

1/15190

0/362‡

FIG4

6:110107636

rs143531641

c.2080A>G

M694V

0/84

1/698*

3/15190

3/9358

FIG4

6:110113852

rs375414729

c.2444T>C

F815S

0/84

1/698

1/15190

1/9358

FUS

16:31201719

rs186547381

c.1292C>T

P431L

0/84

1/698

3/15190

2/9358

FUS

16:31202343

rs201772423

c.1453C>T

R485W

0/84

1/698*

1/15190

1/9358

SETX

9:135140063

rs202121071

c.7597C>T

H2533Y

1/84

0/698

1/15190

1/9358

SETX

9:135147182

rs150673589

c.7114G>A

D2372N

0/84

1/698

19/15190

6/362‡

SETX

9:135202120

rs140781535

c.4865C>T

P1622L

0/84

1/698

1/15190

0/9358

SETX

9:135204004

rs149546633

c.2981A>G

D994G

0/84

1/698

31/15190

0/9358

SETX

9:135204235

rs376022544

c.2750T>C

M917T

0/84

1/698

1/15190

1/9358

Category 4:
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SETX

9:135205116

rs139200312

c.1869A>C

E623D

0/84

1/698

3/15190

3/9358

SETX

9:135205594

rs200614765

c.1391C>T

S464L

0/84

1/698

11/15190

6/9358

SETX

9:135206706

rs372193033

c.968G>A

S323N

0/84

2/698*

1/15190

1/9358

SETX

9:135218103

rs145438764

c.472T>G

L158V

0/84

1/698

53/15190

48/9358

SQSTM1

5:179263547

rs201239306

c.1277C>T

A426V

0/84

1/698

1/15190

0/9358

TAF15

17:34171358

rs140268553

c.1163G>A

R388H

0/84

1/698

7/15190

7/9358

VAPB

20:57014075

rs146459055

c.390T>G

D130E

0/84

1/698

11/15190

11/9358

VAPB

20:57016076

rs143144050

c.510G>A

M170I

0/84

5/698*

19/15190

18/9358
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3.4.4 Variant Data by Gene
ANG
Three ANG variants were identified in ALS patients, all of which were also present in
controls. Two variants have previously been associated with ALS. p.P136L (P112L) was
identified in an FALS subject with an established SOD1 variant and was in 0.006% of controls.
The variant was previously shown to have a deleterious effect on ANG function in cells.37 pK41I
(K17I) was found in ALS subjects in several studies 37–40 however it was also identified in a
healthy control and a subject with a FUS variant. The variant was shown to have a deleterious
effect on protein function37, but is also present in 0.1% of public database controls. The p.K84E
was previously unidentified in ALS, but is in 0.046% of controls. Only p.P136L was predicted to
be damaging by at least two algorithms.
ATXN2
Twelve patients (11 SALS) had one intermediate length ATXN2 alleles of 30-33 CAG
repeats. One of these patients had alleles of 27 and 30 repeats, while the rest had 22 or 23 repeats
on their second allele. A patient with a de novo FUS p.P525L variant had an ATXN2 allele of 31
repeats which was inherited from the unaffected father. An additional 11 patients had one allele
of 27 repeats. Interestingly, two patients with 27 repeats also tested positive for the C9ORF72
repeat expansion. Clinical characteristics of the group carrying intermediate expansions did not
differ from the sporadic ALS cohort as a whole (Table 3.3).
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Table 3.3 Comparison of patient characteristics of ATXN2 intermediate-length expansion carriers
a
n=375, bn=365, cn=7, dn=165

Intermediate (n=12)
Age of onset (median,range)
63.5, 14-79
%FALS
8.3
%Self-reported Caucasian
91.7
%Male
50
Survival in months (median, range) 34, 18-61c

Normal (n=379)
61, 21-85a
10.8
93.2b
57.3
34, 7-147d

p-value
0.764
1
0.61
0.77
0.95

C9ORF72
There were 35 subjects that tested positive for the full hexanucleotide repeat expansion in
C9ORF72 (14 FALS, 21 SALS). In addition, we identified one missense variant by pooledsample sequencing, p.T49R in an FALS subject who also carried the known FUS p.R521G
variant (Table 3.4). We were unable to test for segregation of p.T49R; however an affected
family member was later confirmed by commercial sequencing to carry the R521G mutation.
This variant is present in EVS and 1000genomes at a frequency of 0.01% combined. The p.T49R
variant is predicted to be pathogenic by MutationTaster, but not by PolyPhen2. SIFT was unable
to give a prediction. We did not consider this variant to be pathogenic since there is no
indication that point mutations in C9ORF72 are causative.
DAO
A novel splice-site variant in DAO was discovered in an SALS subject. The c.194+1G>A
variant is predicted to destroy the splice donor site the first coding exon, but tissue from this
individual was not available to determine DAO levels or effects on splicing. We identified two
additional rare variants in the gene: p.G331E in one SALS and p.S345F in one FALS subject.
Both were damaging in at least two predictions.
DCTN1
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We detected two novel variants in DCTN1, both in SALS subjects. The p.S1080F variant
was predicted to be pathogenic by two of three algorithms, while p.H1270Q variant was
predicted to be benign by all three. The p.T1249I variant, which was found in 2 FALS and 1
SALS subjects, was originally considered pathogenic. It has since been shown that the variant
does not segregate with disease and is present in multiple control cohorts (0.29% in ESP6500
and 1000genomes combined) 35. The p.R1049Q variant was identified in patients with
Parkinson’s disease and patients with frontotemportal lobar degeneration35 and is predicted to be
damaging by MutationTaster and PolyPhen2. There was one SALS subject in our cohort with
this variant and 0.14% of controls. We identified three more rare variants were found in our
cohort; p.I935M was found in 1 SALS subject and 4 controls (0.026%) and has two damaging
predictions, p.S111C was found in 1 SALS subject and 1 control (0.006%) and has three
damaging predictions, and p.I196V was found in 1 FALS and 4 SALS subjects and 77 controls
(0.51%). p.I196V is only predicted to be damaging by MutationTaster.
EWSR1
We identified only two variants in EWSR1: a novel variant (p.T207S) in an SALS patient
and a rare variant (p.S203T) also in an SALS patient. Previous studies of EWSR1 have focused
on the C-terminal domain, where pathogenic variants in the related genes TARDBP, FUS, and
TAF15 are found.41 Both of these variants fall within the prion domain, a regions that has not
previously been screened for variants. The novel variant is not predicted as damaging, but the
rare variant (present in 1 control out of 7595) is predicted damaging by MutationTaster and
PolyPhen2.
FIG4
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Five variants were identified in FIG4. A novel 2bp deletion, c.1588_1589delTT, in an
SALS subject results in the formation of a stop codon (ttaTTTgag->ttaTGAg) and is predicted to
cause nonsense-mediated decay. The p.I41T variant identified in an SALS patient was reported
in a compound heterozygous CMT4J patient 36, and is found at a MAF of 0.11% in controls.
p.I41T was predicted to be damaging by all three predictions. Three additional variants have not
been reported in SALS and were very rare in controls. p.T410P and p.F815S were each only
found in one control (0.006%) but had less than two damaging predictions and p.M694V was
found in three (0.02%) and had two damaging predictions.
FUS
Five patients had variants of interest in FUS. The known FUS p.R521G42 variant was
found in an FALS subject. This variant was confirmed in an additional affected family member
by commercial testing. A patient with disease onset at age 14 had the p.P525L variant. Both
parents were negative for the variant. This variant has been previously identified in juvenile
onset cases as a de novo variant.42 We identified a novel deletion c.1394-2delA in the splice
acceptor site of exon 13. An A>G substitution has been reported in the same position and was
shown to cause skipping of exon 14.43 DNA from the affected father was unavailable to test for
segregation. Two variants in FUS p.R485W and p.P431L were present in controls but at very
low frequencies (only 1 sample and 3 samples respectively out of 7595). pR485W was predicted
to be damaging by SIFT and MutationTaster, but not PolyPhen2 while p.P431L was predicted to
be damaging by all three.
OPTN
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We found a novel OPTN nonsense variant (p.Q235X) in an apparently sporadic subject.
Nonsense variants both upstream and downstream of this codon have been reported in other
subjects with ALS. p.Q23X and p.Q165X were both dominantly inherited and predicted by
SIFT to undergo nonsense-mediated decay (NMD).44,45 The downstream variant p.Q398X was
recessively inherited and NMD was experimentally observed.46,47 We also identified the variant
p.Q314L in one SALS subject. This variant was reported as a disease variant44, but is now
present in controls at a very low frequency (0.02%). It is predicted to be damaging by all three
algorithms.
SETX
A notable finding was the abundance of novel SETX variants. We found 18 SETX
variants in 30 subjects. Seven of the variant were novel. Two variants were novel, but in the
same residue as a previously reported variant. We identified a p.T1118K variant (p.T1118I was
identified in a Chinese cohort48) and a p.M274V variant (p.M274I was reported in an autosomal
recessive ataxia with peripheral neuropathy49) both in SALS patients. The remaining 5 novel
variants (p.E327V, p. T14I, p.R168Q, p.A1588T, and p.K220Q) were identified in SALS
patients as well. Only p.A1588T and p.M274V were not damaging in at least two predictions.
There were 8 SALS and 2 FALS subjects that carried the p.I2547T variant which has
previously been reported in ALS.50 One SALS subject was homozygous for the variant.
Recessive mutations in SETX are the cause of ataxia-ocular apraxia 2 (AOA2)51 and to our
knowledge, this is the first report of a possibly recessive mutations in SETX causing ALS.
Another patient was compound heterozygous for the p.I2547T variant along with the novel
p.T14I variant, however they also carried a pathogenic p.R408C variant in TAF15. The variant is
present at a MAF of 0.5% in controls with one homozygous subject out of 7595. It is predicted to
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be damaging by MutationTaster, but not SIFT or PolyPhen2. The variant p.C1554G was also
reported as pathogenic50 and is present in controls (MAF=0.3%). One subject was compound
heterozygous for this variant and a novel p.R168Q variant. It was found in 5 additional SALS
subjects and is predicted to be damaging by all three predictions.
Nine of the SETX variants were never reported in ALS and are rare in controls. Five of
these (p.H2533Y (0.006%), p.D2372N (0.1%), p.P1622L (0.006%), p.D994G (0.2%), and
p.M917T (0.006%)) were predicted to be damaging in fewer than two predictions. p.E623D
(0.02%), p.S464L (0.07%) and p.S323N (0.006%) were predicted to be damaging by two
algorithms and p.L158V (0.3%) was predicted to be damaging by all three. Despite the high
number of variants in SETX, we did not find a significant association with individual SNPs or
combined across the gene.
SOD1
We identified 7 different SOD1 variants in 10 subjects: p.A5V(A4V)52, p.G38R(G37R)52,
p.D77Y(D76Y)53, p.A90V(A89V)54, p.D91A(D90A)55, p.I114T(I113T)52, and the novel variant
p.67S. The 6 known variants were all predicted to be damaging by at least two predictions,
except for p.D91A, which was not predicted to be damaging in any. The p.D91A variant has
been observed in both recessive and dominant inheritance.55 We identified one SALS subject
that was homozygous for the variant. One individual with definite FALS was heterozygous for
the p.D91A variant, but two affected family members in their pedigree that were also included in
the study did not possess this variant. Instead, those two individuals were positive for the
C9ORF72 repeat expansion. Previously known p.A5V and p.I114T variants were detected in
SALS subjects. DNA from family members was unavailable for segregation testing in both
cases. We also discovered a novel p.P67A variant in a subject with probable FALS that is likely
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causative. This variant segregated with disease in additional affected family members and is
predicted to be damaging by PolyPhen2, SIFT, and MutationTaster. Furthermore, two variants in
the same amino-acid (p.P67S(P66S)56 and p.P67R(P66R)40) have previously been reported to
cause disease.
SQSTM1
Four variants in SQSTM1 were identified in SALS patients and one in an FALS patient.
p.L48P and was novel and predicted pathogenic in two out of three predictions. The p.A33V (2
SALS), p.V153I (1 FALS), and p.K283E (5 SALS) variants were previously identified as
pathogenic57,58, but were seen in 0.04%, 0.06%, and 0.27% of controls respectively. p.A33V and
p.K283E were both predicted damaging at least twice, but p.V153I was only predicted to be
damaging once. One more variant with a MAF of 0.006% in controls, p.A46V, was identified in
an SALS subject. This variant was predicted to be damaging twice.
TAF15
Two TAF15 variants, p.R408C and p.R388H, were present in SALS subjects. Both of
these variants were previously found in ALS patients; however p.R388H was identified in
controls at the same time and was not considered pathogenic. The p.R408C variant has now also
been found in controls, but was previously shown to result in cytoplasmic foci in transfected
cells.59 Both variants were predicted to be damaging in at least two predictions.
TARDBP
We identified three TARDBP variants, one of which is novel. A subject from a
previously reported family was found to carry p.A315T variant.60 A sporadic subject was found
to carry a known pathogenic variant, p.G287S.61 Finally, a novel variant, p.S375G, was found in
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another SALS subject. The variant was inherited from a parent who was unaffected at age 80
while the subject with ALS had age of onset of 41. It is unclear whether this variant is benign or
pathogenic and incompletely penetrant. The p.S375G was not predicted to be damaging by any
of the three algorithms used, however the two known pathogenic variants are both only predicted
to be damaging by MutationTaster.
VAPB
There were no novel or disease-associated variants in VAPB. Two variants, p.D130E and
p.M170I, were rare in controls (0.072% and 0.13% respectively). p.D130E was in 1 SALS
subject and was not predicted to be damaging. p.M170I was found in 5 SALS subjects and was
predicted to be damaging by MutationTaster and PolyPhen2.
VCP
One known VCP variant p.R155H62 was detected in a subject with FALS and segregated
with disease among siblings, one of whom has Paget's disease. Their affected parent died of ALS
complicated by non-Alzheimer dementia.

3.4.5 Prevalence of variants in ALS genes
We considered 65 of the rare and novel variants identified by sequencing to be potentially
pathogenic. 83 subjects (21.2% overall, 35.7% in FALS and 19.5% in SALS) carried at least one
of these variants. The C9ORF72 repeat expansion (found in 8.7% of subjects, n=34) and ATXN2
intermediate-length CAG repeats (found in 3.1% of subjects, n=12) were also considered to be
potentially pathogenic. In total, 124 subjects (31.7% overall; 64.3% across all categories of
FALS, 27.8% in SALS) carried one or more of these potentially pathogenic variants
(Supplementary Table S1), a higher number than reported in many prior studies.8–12,14
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The proportion of subjects carrying a potentially pathogenic variant was heavily
influenced by the strength of evidence for familial transmission of ALS (Table 3.4), with the
highest rate of variant discovery in definite FALS (81.6%). The frequency of variants declined
with less evidence for transmission, but even 27.8% of sporadic/simplex subjects were carriers.
Table 3.4 Prevalence of variants in ALS genes by family categorization. Familial ALS categories were assigned
according to recently proposed criteria.13,63 Definite FALS (38% of families): at least 2 first- or second-degree
relatives with ALS. Probable A FALS (7% of families): 1 first-degree relative with ALS. Probable B FALS (43% of
families): 1 second-degree relative with ALS. Possible FALS (12% of families): 1 distant relative with ALS.
Sporadic ALS (89% of entire cohort): all subjects not meeting criteria for any FALS category. ALS = amyotrophic
lateral sclerosis; FALS = familial ALS.

Sporadic
Total Subjects
ANG
ATXN2
C9ORF72
DAO
DCTN1
EWSR1
FIG4
FUS
OPTN
SETX
SOD1
SQSTM1
TAF15
TARDBP
UBQLN2
VAPB
VCP
Total Variants
Subjects with any variant
% Subjects with variants

349
2
11
21
2
10
2
5
3
2
29
4
9
2
2
6
110
97
27.8%

All
FALS
42
1
1
15
1
3
2
3
6
1
1
1
35
27
64.3%

Definite
16
1
8
1
2
1
1
4
1
19
13
81.3%

Probable A Probable B
3
1
1
2
2
66.7%

18
1
6
2
2
1
12
10
55.6%

Possible
5
1
1
2
2
40.0%

We identified 4 sporadic subjects with potentially recessive causes of their ALS (Table
3.5). One subject was homozygous for SOD1 p.D91A (D90A), while three others carried two
mutations in SETX. One subject tested homozygous for SETX p.I2547T, but we did not exclude
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the possibility of a deletion on one allele. The two additional subjects could each be compound
heterozygotes comprised of a rare variant (p.C1554G or p.I2547T with 0.3% and 0.5% MAF in
population database respectively) and a novel variant (p.R168Q or p.T14I respectively). The
subject carrying p.I2547T and p.T14I was also heterozygous for TAF15 p.R408C which has
previously been reported in a subject with SALS.59 Due to the absence of additional family
members for segregation or tissue for cDNA sequencing, we were unable to determine if these
SETX variants are in cis or trans. Because recessive mutations in SETX are associated with
ataxia-ocular apraxia type 2 (OMIM 606002) and SETX-associated ALS is dominantly inherited,
we reviewed the medical records of these 3 individuals. All three showed typical ALS disease
course without clinically apparent eye movement abnormalities or ataxia.
We also identified a pedigree with FALS with independently-segregating causative
mutations (Figure 2). The proband, three affected siblings and a first cousin once-removed all
tested positive for the C9ORF72 repeat expansion. Another first cousin once-removed was
diagnosed with ALS at another center test but tested negative for the expansion, including by
Southern blot (See figure X in chapterX). Instead, this individual was found to carry a
heterozygous SOD1 p.D91A mutation detected by pooled-sample sequencing.

Figure 3.2 Segregation of independent mutations in an ALS family
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3.4.6 Prevalence of potential oligogenic subjects
We assessed the number of genes with potentially pathogenic rare variants in each
individual. Fifteen subjects (3.8% overall, 14% in FALS, 2.6% in SALS) harbored potentially
pathogenic variants in at least two ALS genes: 11 with variants in two ALS genes, while 4 had
variants in three genes each (Table 3.5). Although one subject had a FUS p.R521G variant and a
C9ORF72 p.T49R variant, they were not included as potentially oligogenic since we did not
consider point mutations in C9ORF72 as pathogenic.
Six potentially oligogenic subjects had a family history of ALS subjects and in all cases
one of their variants was either the C9ORF72 repeat expansion or a missense variant in SOD1 in
combination with additional rare or novel variant(s), several of which have also been previously
reported in ALS subjects. Interestingly, one FALS proband carried 3 variants, each of which has
previously been reported as pathogenic: SOD1 p.G38R, ANG p.P136L, and DCTN1 p.T1249I.
Nine apparently sporadic subjects had variants in multiple genes (Table 3.5), but only
two were well-established ALS mutations: TARDBP p.G287S was found in combination with
VAPB p.M170I while a subject with juvenile-onset ALS carried a de novo FUS p.P525L
mutation with a paternally-inherited intermediate-sized CAG expansion in ATXN2. Two SALS
patients carried multiple ALS-associated variants that are rare in population databases (ANG
p.K41I with VAPB p.M170I and TAF15 p.R408C with SETX p.I2547T and SETX p.T14I).
To compare the frequency of “oligogenic” cases in ALS to other populations, we used
exomes from 114 subjects diagnosed with CMT1 (n=4), dHMN (n=1), EA (n=5), EVO (n=2),
GSM1 (n=7), IBM (n=40), LGMD (n=5), MDC (n=11), MELAS (n=1), MFM (n=6), MPD
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(n=8) , NVS (n=1), SFN (n=20), SMA (n=3). We compared these exomes to 614 ALS subjects
(some of which were also included in pooled-sample sequencing). Since the non-ALS subjects
were not screened for repeat expansions in C9ORF72 and ATXN2, we performed our comparison
using only the 15 other genes under investigation. The proportion of subjects carrying variants in
more than one gene was not higher in ALS subjects (6.02%) compared to non ALS subjects
(6.1%).

Variant 1

Table 3.5 Subjects with multiple variants in ALS genes
Variant 2
Variant 3

Possible model

Sporadic

SOD1(p.D91A)

SOD1(p.D91A)

-

Homozygous recessive

Sporadic

SETX(p.I2547T)

SETX(p.I2547T)

-

Homozygous recessive

Sporadic

SETX(p.C1554G)

SETX(p.R168Q)

-

Potential compound het

Familial

SOD1(p.A5V)

DAO(p.S345F)

-

Oligogenic

Familial

SOD1(p.P67A)

SETX(p.I2547T)

-

Oligogenic

Familial

C9ORF72

DCTN1(p.I196V)

-

Oligogenic

Familial

C9ORF72

SQSTM1(p.V153I)

-

Oligogenic

Familial

C9ORF72

SETX(p.I2547T)

-

Oligogenic

Familial

FUS(p.R521G)

C9ORF72(p.T49R)

-

-

Sporadic

ANG(p.K41I)

VAPB(p.M170I)

-

Oligogenic

Sporadic

ATXN2(22/31)

SQSTM1(p.K238E)

-

Oligogenic

Sporadic

FUS(p.R485W)

SETX(p.I2547T)

-

Oligogenic

Sporadic

DCTN1(p.R1049Q)

SETX(p.S323N)

-

Oligogenic

Sporadic

FUS(p.P525L)

ATXN2(23/31)

-

Oligogenic

Sporadic

TARDBP(p.G287S)

VAPB(p.M170I)

-

Oligogenic

Familial

SOD1(p.G38R)

ANG(p.P136L)

DCTN1(p.T1249I)

Oligogenic

Sporadic

ATXN2(22/32)

DCTN1(p.T1249I)

SETX(p.M274V)

Oligogenic

Sporadic

TAF15(p.R408C)

SETX(p.I2547T)

SETX(p.T14I)

Sporadic

SETX(p.C1554G)

DCTN1(p.H1270Q)

FIG4(p.M694V)

Oligogenic, potential
compound het
Oligogenic

3.4.7 Correlation of variant genes with disease characteristics
In an oligogenic model of disease, the additive or synergistic effects of multiple variants
can influence not only the risk of developing disease, but also phenotypic manifestations of the
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disease. Age at symptom onset was significantly earlier in cases carrying variants in multiple
genes (median=46, IQR=39-61) compared to all other subjects (median=61, IQR=51-70,
p=0.0046) and when compared to cases with mutations in just one gene (median=60, IQR=4860, p=0.017). Even when the subject with juvenile onset was removed a difference of 10 years
earlier remained (median=50.5, IQR=40.25-61.5, p=0.013 against all others and p=0.041 against
other single-gene variant carriers). Furthermore, there was a weak, but statistically significant
negative correlation between age of onset and the number of genes with variants (spearman’s
rho=-0.11, p=0.024). The number of ALS genes with variants did not influence disease duration
or site of onset in our cohort.

3.4.8 Rare variants as modifiers of ALS risk
We also used our sequencing results to search for single variants in known ALS genes
that increased or decreased ALS risk. To do so, we analyzed all coding variants found in our
ALS cohort and also present in population databases (n=61, with 47 having a population MAF
<1%). Three SNPs in SETX (rs1183768, rs543573, and rs2296871) were in perfect linkage
disequilibrium and were considered to be one signal represented by rs2296871. We included
only ALS subjects of European ancestry and compared to controls of European ancestry from
ESP6500 and the 1000 Genomes Project. SPLINTER-predicted allele frequencies were used for
common variants that were not confirmed by genotyping in ALS subjects. Using a Bonferonnicorrected significance level of 8.2x10-4, 3 variants were significantly more common in our ALS
discovery cohort (rs3739927 and rs882709 in SETX, and rs41311143 in EWSR1). To follow up,
we genotyped these 3 SNPs and 28 additional candidate variants in a validation cohort of 552
sporadic ALS cases and 464 controls from Coriell reference panels. However, none of the 31
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tested variants showed a significant association with ALS in either direction (Supplementary
Table S2).
We also asked whether the burden of rare coding variants in any of the tested ALS genes
was higher in sporadic subjects compared to controls using SKAT (Table 3.6).33 After correcting
for multiple tests (α=3.57x10-3), SOD1 was the only gene that showed a significant association
(p=1.59x10-5) while TARDBP and VAPB approached statistical significance (p=5.57x10-3 and
p=5.99x10-3 respectively).
Table 3.6 Gene-based rare variant association tests. Association tests were performed with SKAT using the
optimal.adj method and the default linear, weighted kernel, with significance level=3.57x10-3. Only coding variants
with minor allele frequencies <1% were included in the analysis. Only subjects of European Ancestry were used
from our cohort and controls (ESP6500+1000genomesEUR).
Gene
P-value # Markers
SOD1

1.59x10-3

4

TARDBP

5.57x10-3

10

VAPB

5.99x10-3

8

SQSTM1

0.126

39

SETX

0.165

125

FUS

0.323

25

DAO

0.425

26

DCTN1

0.443

58

EWSR1

0.450

21

ANG

0.487

9

TAF15

0.573

34

VCP

0.693

5

OPTN

0.765

20

FIG4

0.863

32
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3.5 Discussion
Rapid progress toward defining the genetic landscape of ALS has been fueled by the
emergence of next-generation sequencing. In this study, we used the efficiency and power of
pooled-sample sequencing to investigate the frequency of pathogenic and potentially-pathogenic
variants in known ALS genes in a large cohort of US patients. Our approach produced highly
accurate sequence data for 16 known genes in a time, sample, and cost-efficient manner. We
estimated that this study required 83% less DNA per subject and cost 10% of performing the
equivalent study by traditional Sanger sequencing. In doing so, we have generated the most
comprehensively sequenced North American cohort to date.
In this group of subjects we identified 27 novel variants (i.e. not found in databases of
variation) and an additional 39 that are very rare in control populations. Not surprisingly, the
highest rate of variant detection occurred in families with the strongest ALS histories: we found
explanatory mutations in 80% of these pedigrees. This rate is higher than many previous reports
of all FALS8–14 and partially stems from our use of a strict definition of familial ALS favoring
pedigrees with clearly dominant transmission patterns that undoubtedly enrich for Mendelian
genes. Our elevated variant detection rate is also influenced by the large number genes analyzed
in each family. Because our cohort was a clinic-based, we cannot address whether differences in
populations are also involved.
Although the frequency of variant detection in our sporadic ALS subjects was lower than
in familial ALS, it was still 28%. This is considerably higher than other studies 8–12,14, likely due
in part to the large number of genes we sequenced. In support of this, we note that the frequency
of variants in commonly sequenced genes (e.g. C9ORF72, SOD1, TARDBP) was within
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previously reported ranges. To directly compare our findings with a similar study of an Irish
population9, we limited both data sets to genes shared between the two studies and only included
novel variants (i.e. not seen in any population database). The total number of subjects found
with at least one potentially pathogenic mutation was 16.4% in this study compared to 12.8% in
the Irish population. This difference is not statistically significant (p=0.12) and was driven by
the absence of SOD1 mutations in the Irish cohort. These broad differences in populations need
to be given appropriate consideration when genetic testing or counseling is being provided to
patients.
Based on previous reports of oligogenic inheritance in ALS, we looked for subjects with
potentially pathogenic variants in more than one ALS gene. We found mutations in at least two
ALS genes in 3.8% of our subjects (14% in FALS, 2.6% in SALS). In most cases, 1 of the
identified variants is a known mutation with clearly established pathogenicity; however, many of
the additional variants are of unknown significance. It is possible that these additional variants
co-occur with pathogenic mutations by chance. However, the finding that subjects with
potentially pathogenic variants in >1 gene had disease onset 10 years earlier than other subjects
supports a model of ALS where the additive or synergistic effects of multiple defective genes
increase risk and influence disease phenotype.
The rate of potentially oligogenic cases in our cohort is higher than in prior reports, but
direct comparisons are prevented by differences in i) which genes were sequenced, ii) how
complete variant ascertainment was, iii) relative numbers of familial and sporadic cases, and iv)
which variants were considered to be potentially pathogenic. We were able to use exome
sequencing from subjects with ALS to compare the frequency of subjects with mutations in more
than one ALS gene to other non-ALS disorders. Both cohorts had a rate of ~6% overall.
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Although this is higher than the rate we discovered in our pooled-sample sequencing cohort, this
could be explained by the different sequencing techniques. In contrast to the ALS cohort the
majority of non-ALS cases did not carry a well-established ALS mutation. An equal rate of
oligogenic cases in ALS and non-ALS cases supports the hypothesis that carrying mutations in
multiple genes is not a risk factor for disease, but influences disease progression.
This study evaluated known ALS genes only. With many efforts underway to generate
exome and genome-wide variant data on large numbers of ALS patients, these types of
interactions should become easier to detect and validate. These large datasets should also allow
unbiased searches for new ALS genes using rare variant burden testing. As a test of this
principle, we asked whether rare variant burden testing would identify any of the known ALS
genes we sequenced. In our modestly-sized cohort we demonstrated a significant association for
SOD1 and suggestive associations for TARDBP and VAPB. We also noticed an abundance of
variants in the SETX gene, an intriguing finding that was also evident in a prior study.9 These
findings predict that well-powered genome-wide studies will identify new ALS genes.
Our study also highlights important lessons regarding mutation screening in ALS. First,
a significant number of individuals will harbor more than one potentially pathogenic mutation.
This fact dramatically influences estimates of transmission risk and even prognosis. Therefore,
comprehensive screening of known genes is preferable to single-gene testing and made more
cost-effective by next-generation approaches to sequencing. Second, as our pedigree with
independently segregating SOD1 and C9ORF72 mutations demonstrates, even once a causative
mutation has been identified in a pedigree, each affected individual should be sequenced for
confirmation. Third, despite the frequency with which our study found variants in ALS subjects,
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36% of FALS and 74% of SALS subjects had no variants in any of 17 ALS genes we analyzed.
Efforts are therefore needed to identify additional genes influencing ALS risk.
Finally, we note that many of the novel and rare variants identified by this study and
others are of unknown significance and will require further study to validate a possible
contribution to ALS pathogenesis. The complexity of determining pathogenicity of variants is
highlighted by the 13 variants we identified that had been previously associated with ALS but
have since been found in control databases at rates higher than expected for moderate or high
penetrance mutations. Although these variants could represent mutations with reduced
penetrance, or the presence of pre-symptomatic individuals in control populations, they most
likely result from including limited controls in the original studies. In fact, many variants
previously reported as pathogenic for ALS and other diseases are now found in the 1000
Genomes Project or the Exome Sequencing Project at frequencies exceeding those expected for
moderately or highly penetrant mutations.64 To prevent the literature from becoming confused
with disease-associated variants that are not pathogenic, we support increased attention to
variants are reported in disease populations, including the creation of levels of genetic evidence
for pathogenicity as recently proposed.65
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3.6 Supplementary tables
Table S1. Clinical characteristics of variant carriers.
Age of Onset
Patient Variant(s)

Family Type

Ethnicity

Sex

Site of onset

Survival (months)

(years)
ANG(p.K41I),
Simplex

Caucasian

Female

45

Limb

unknown

ANG(p.K84E)

Simplex

African American

Female

43

Limb

>78

ATXN2(22/30)

Simplex

Caucasian

Male

65

Limb

unknown

ATXN2(22/30)

Simplex

Caucasian

Female

57

Unknown

unknown

ATXN2(22/30)

Simplex

Caucasian

Male

66

Limb

61

ATXN2(22/31)

Simplex

Caucasian

Female

79

Limb

unknown

ATXN2(22/31)

Probable B

Caucasian

Male

70

Bulbar

33

ATXN2(22/31)

Simplex

Caucasian

Female

47

Limb

42

ATXN2(22/32)

Simplex

Caucasian

Male

71

Limb

30

ATXN2(23/30)

Simplex

African American

Male

41

Limb

>25

ATXN2(27/30)

Simplex

Caucasian

Female

67

Bulbar

22

C9ORF72

Simplex

Unknown

Female

58

Limb

unknown

C9ORF72

Simplex

Caucasian

Female

60

Limb

unknown

C9ORF72

Simplex

Caucasian

Female

59

Limb

unknown

C9ORF72

Simplex

Caucasian

Male

59

Limb

unknown

C9ORF72

Simplex

Caucasian

Male

72

Limb

unknown

C9ORF72

Simplex

Caucasian

Female

44

Bulbar

29

C9ORF72

Simplex

Caucasian

Male

58

Bulbar

25

C9ORF72

Definite

Caucasian

Male

57

Bulbar

37

C9ORF72

Simplex

Caucasian

Male

50

Limb

29

C9ORF72

Probable B

Caucasian

Female

63

Limb

12

C9ORF72

Definite

Caucasian

Male

45

Limb

>71

C9ORF72

Definite

Caucasian

Male

46

Limb

57

C9ORF72

Definite

Caucasian

Male

64

Limb

62

C9ORF72

Simplex

Caucasian

Male

53

Limb

31

C9ORF72

Probable B

Caucasian

Male

46

Limb

>40

VAPB(p.M170I)

84

C9ORF72

Simplex

Caucasian

Male

69

Limb

19

C9ORF72

Simplex

Caucasian

Male

48

Bulbar

28

C9ORF72

Definite

Caucasian

Female

51

Bulbar

29

C9ORF72

Simplex

Caucasian

Female

57

Limb

21

C9ORF72

Simplex

African American

Female

52

Limb

24

C9ORF72

Simplex

Caucasian

Male

65

Limb

54

C9ORF72

Probable B

Caucasian

Female

48

Bulbar

41

C9ORF72

Simplex

Caucasian

Female

57

Limb

42

C9ORF72

Simplex

Caucasian

Female

51

Limb

27

C9ORF72

Simplex

Caucasian

Female

56

Bulbar

30

C9ORF72

Probable B

Caucasian

Male

44

FTD

146

C9ORF72

Probable B

Caucasian

Male

63

Limb

46

C9ORF72

Probable A

Caucasian

Female

76

Limb

17

C9ORF72

Simplex

Caucasian

Female

63

Limb

36

C9ORF72

Simplex

Caucasian

Male

56

Limb

46

C9ORF72

Simplex

Caucasian

Female

70

Limb

27

C9ORF72

Simplex

Caucasian

Female

63

Limb

50

Definite

Caucasian

Male

60

Bulbar

20

Definite

Caucasian

Male

46

Bulbar

33

Probable B

Caucasian

Female

63

Limb

32

DAO(p.G331E)

Simplex

Caucasian

Male

57

Limb

unknown

DAO(splice donor)

Simplex

Caucasian

Female

71

Bulbar

29

Simplex

Caucasian

Female

41

Limb

>50

DCTN1(p.I196V)

Simplex

Caucasian

Male

57

Bulbar

unknown

DCTN1(p.I196V)

Simplex

Caucasian

Female

30

Limb

unknown

DCTN1(p.I196V)

Simplex

Caucasian

Female

38

Limb

unknown

DCTN1(p.I196V)

Simplex

Caucasian

Female

69

Bulbar

22

C9ORF72,
DCTN1(p.I196V)
C9ORF72,
SETX(p.I2547T)
C9ORF72,
SQSTM1(p.V153I)

DCTN1(p.H1270Q),
FIG4(p.M694V),
SETX(p.C1554G)

85

DCTN1(p.I935M)

Simplex

Hispanic

Male

81

Limb

unknown

Simplex

Caucasian

Male

69

Limb

38

DCTN1(p.S1080F)

Simplex

African American

Male

64

Limb

>135

DCTN1(p.S111C)

Simplex

Caucasian

Female

71

Limb

>54

DCTN1(p.T1249I)

Possible

Caucasian

Male

69

Bulbar

65

Simplex

Caucasian

Female

62

Limb

unknown

EWSR1(p.S203T)

Simplex

Caucasian

Male

61

Limb
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EWSR1(p.T207S)

Simplex

Caucasian

Female

60

Limb

unknown

FIG4(F530*)

Simplex

Caucasian

Male

82

Limb

16

FIG4(p.F815S)

Simplex

Caucasian

Male

38

Bulbar

unknown

FIG4(p.I41T)

Simplex

Caucasian

Female

77

Bulbar

7

FIG4(p.T410P)

Simplex

Hispanic

Male

78

Bulbar

unknown

FUS(p.c.1394-2delA)

Possible

Caucasian

Male

32

Limb

8

FUS(p.P431L)

Simplex

Caucasian

Male

60

Limb

unknown

Simplex

Caucasian

Female

14

Limb

44

Simplex

Caucasian

Male

55

Limb

>62

FUS(p.R521G)

Definite

Caucasian

Female

46

Limb

20

OPTN(p.Q235*)

Simplex

Caucasian

Male

72

Limb

14

OPTN(p.Q314L)

Simplex

Caucasian

Female

63

Bulbar

unknown

SETX(p.A1588T)

Simplex

Asian

Male

48

Limb

unknown

SETX(p.C1554G)

Simplex

Caucasian

Male

78

Bulbar

unknown

SETX(p.C1554G)

Simplex

Caucasian

Male

69

Limb

unknown

SETX(p.C1554G)

Simplex

Caucasian

Male

74

Limb

unknown

SETX(p.C1554G)

Simplex

Caucasian

Female

69

Limb

unknown

Simplex

Caucasian

Female

67

Bulbar

unknown

Simplex

Hispanic

Male

53

Bulbar

unknown

DCTN1(p.R1049Q),
SETX(p.S323N)

DCTN1(p.T1249I),
SETX(p.M274V),
ATXN2(22/32)

FUS(p.P525L),
ATXN2(23/31)
FUS(p.R485W),
SETX(p.I2547T)

SETX(p.C1554G),
SETX(p.R168Q)
SETX(p.D2372N)

86

SETX(p.D994G)

Simplex

Caucasian

Male

70

Unknown

unknown

SETX(p.E327V)

Simplex

Caucasian

Male

60

Limb

>205

SETX(p.E623D)

Simplex

Caucasian

Male

67

Limb

>28

SETX(p.H2533Y)

Probable B

Caucasian

Female

59

Limb

41

SETX(p.I2547T)

Simplex

Caucasian

Male

61

Limb

unknown

SETX(p.I2547T)

Simplex

Caucasian

Male

35

Bulbar

unknown

SETX(p.I2547T)

Simplex

Caucasian

Female

77

Respiratory

unknown

SETX(p.I2547T)

Simplex

Unknown

Male

68

Limb

unknown

Simplex

Caucasian

Male

51

Limb

32

Simplex

Caucasian

Female

40

Limb

36

SETX(p.K220Q)

Simplex

Caucasian

Male

72

Bulbar

19

SETX(p.L158V)

Simplex

Caucasian

Male

43

Limb

>55

SETX(p.M917T)

Simplex

Caucasian

Male

40

Limb

16

SETX(p.P1622L)

Simplex

Caucasian

Male

41

Limb

59

SETX(p.S323N)

Simplex

Caucasian

Female

79

Limb

unknown

SETX(p.S464L)

Simplex

Caucasian

Female

39

Limb

129

SETX(p.T1118K)

Simplex

Caucasian

Male

62

Limb

unknown

SOD1(p.A5V)

Simplex

Caucasian

Female

46

Limb

unknown

Definite

Caucasian

Female

57

Limb

13

SOD1(p.A90V)

Simplex

Caucasian

Male

unknown

Limb

unknown

SOD1(p.D77Y)

Probable B

Caucasian

Male

75

Limb

41

SOD1(p.D91A)

Simplex

Caucasian

Male

68

Limb

unknown

SOD1(p.D91A)

Definite

Caucasian

Female

unknown

Limb

unknown

Definite

Caucasian

Female

21

Limb

unknown

SOD1(p.I114T)

Simplex

Caucasian

Male

66

Limb

unknown

SOD1(p.I114T)

Definite

Caucasian

Female

39

Limb

unknown

SETX(p.I2547T)
homozygous
SETX(p.I2547T),
SETX(p.T14I),
TAF15(p.R408C)

SOD1(p.A5V),
DAO(p.S345F)

SOD1(p.G38R),
ANG(p.P136L),
DCTN1(p.T1249I)

87

SOD1(p.P67A),
Probable B

Caucasian

Female

36

Limb

>95

SQSTM1(p.A33V)

Simplex

Caucasian

Male

63

Bulbar

unknown

SQSTM1(p.A33V)

Simplex

Caucasian

Male

82

Bulbar

25

SQSTM1(p.A426V)

Simplex

Caucasian

Male

76

Bulbar

84

SQSTM1(p.K238E)

Simplex

Caucasian

Male

75

Limb

unknown

SQSTM1(p.K238E)

Simplex

Caucasian

Male

34

Limb

unknown

SQSTM1(p.K238E)

Simplex

Caucasian

Male

61

Limb

unknown

SQSTM1(p.K238E)

Simplex

Caucasian

Male

39

Limb

>108

Simplex

Caucasian

Male

38

Bulbar

18

SQSTM1(p.L48P)

Simplex

Caucasian

Male

64

Limb

100

TAF15(p.R388H)

Simplex

Caucasian

Female

62

Limb

unknown

TARDBP(p.A315T)

Definite

Caucasian

Male

48

Limb

118

Simplex

Caucasian

Female

72

Bulbar

102

TARDBP(p.S375G)

Simplex

Caucasian

Female

41

Limb

10

VAPB(p.D130E)

Simplex

Caucasian

Male

54

Limb

73

VAPB(p.M170I)

Simplex

Caucasian

Male

74

Limb

unknown

VAPB(p.M170I)

Simplex

Caucasian

Male

67

Bulbar

unknown

VAPB(p.M170I)

Simplex

Caucasian

Male

38

Limb

>71

VCP(p.R155H)

Probable A

Caucasian

Male

42

Limb

>137

SETX(p.I2547T)

SQSTM1(p.K238E),
ATXN2(22/31)

TARDBP(p.G287S),
VAPB(p.M170I)

88

Table S2 Individual variant association testing results. Only SNPs found ALS samples with European ancestry. Discovery Cohort= ALS: genotyped frequencies.
SPLINTER predictions used when SNPs not genotyped. Only samples of European ancestry used. Controls: Frequency in ESP6500-EA+1000genomesEUR.
Significance level adjusted for multiple comparisons p=8.2x10-4. Validation Cohort: 552 ALS cases and 464 neurologically normal controls from Coriell, all of
European Ancestry. Yellow highlights three variants with significant association in the Discovery Cohort, but that did not show an association with the
Validation Cohort.
Discovery Cohort
SNP ID

Hg19 Location

Gene

Variant

Alleles

Validation Cohort

Minor Alleles
ALS
Controls

pval

OR (95%CI)

Minor Alleles
ALS
Controls

pval

OR (95%CI)

rs80356719

1:11082325

TARDBP

G287S

A/G

1/618

0/9358

0.062

Inf (0.39,Inf)

not tested – singleton in ALS

Novel

1:11082589

TARDBP

S375G

G/A

1/618

0/9358

0.062

Inf (0.39,Inf)

not tested – singleton in ALS

Novel

2:74588653

DCTN1

H1270Q

A/C

1/618

0/9358

0.062

Inf (0.39,Inf)

not tested – singleton in ALS

rs72466496

2:74588717

DCTN1

T1249I

T/C

1/618

39/9358

0.515

0.39 (0.01,2.3)

rs72659383

2:74592252

DCTN1

R1049Q

A/G

1/618

21/9358

1

0.72 (0.02,4.5)

rs17721059

2:74596527

DCTN1

R495Q

A/G

19/618

175/9358

0.048

1.66 (0.97,2.7)

rs13420401

2:74597937

DCTN1

L287M

A/C

2/618

6/9358

0.084

rs55862001

2:74598723

DCTN1

I196V

G/A

4/618

70/9358

1

rs374419252

2:74604801

DCTN1

S111C

G/C

1/618

0/9358

0.062

rs200396166

5:179248034

SQSTM1

A33V

T/C

2/618

6/9358

Novel

5:179248079

SQSTM1

L48P

C/T

1/618

rs11548633

5:179252184

SQSTM1

K238E

G/A

rs55793208

5:179260099

SQSTM1

E274D

rs201239306

5:179263547

SQSTM1

A426V

6/1080

1/910

0.13

5.08
(0.61,233.59)

not tested
24/1076

19/908

0.88

1.07
(0.56,2.08)

0/1084

0/738

1

0 (0,Inf)

6/1070

6/904

0.78

0.84
(0.23,3.17)

Inf (0.39,Inf)

0/1082

0/738

1

0 (0,Inf)

0.105

4.4
(0.43,24.67)

0/1062

2/904

0.21

0 (0,4.53)

0/9358

0.062

Inf (0.39,Inf)

5/618

32/9358

0.076

2.38
(0.72,6.18)

5/1082

1/738

0.41

T/G

5/618

235/9358

4.11E-03

0.32 (0.1,0.75)

27/1090

22/920

1

T/C

1/618

0/9358

0.062

Inf (0.39,Inf)

89

5.06
(0.5,28.37)
0.86
(0.23,2.32)

not tested – singleton in ALS
3.42
(0.38,161.93)
1.04
(0.56,1.92)

not tested – singleton in ALS

rs121908287

6:110036336

FIG4

I41T

C/T

1/618

16/9358

1

rs2295837

6:110064928

FIG4

M364L

T/A

14/618

345/9358

0.073

rs9885672

6:110107517

FIG4

V654A

C/T

80/618

1432/9358

0.118

rs143531641

6:110107636

FIG4

M694V

G/A

1/618

3/9358

0.226

rs375414729

6:110113852

FIG4

F815S

C/T

1/618

1/9358

0.12

rs3739927

9:135139826

SETX

S2612G

G/A

34/618

249/9358

2.21E-04

rs1056899

9:135139901

SETX

I2587V

G/A

191/618

2752/9358

0.439

rs151117904

9:135140020

SETX

I2547T

C/T

7/618

71/9358

rs2296871

9:135173685

SETX

T1855A

G/A

126/618

rs140781535

9:135202120

SETX

P1622L

T/C

rs112089123

9:135202325

SETX

C1554G

rs1185193

9:135203409

SETX

rs3739922

9:135203530

Novel

0.95
(0.02,6.11)
0.61
(0.33,1.04)
0.82
(0.64,1.05)
5.05
(0.1,63.11)
15.15
(0.19,1177.85)
2.13
(1.43,3.09)

0/1044

3/868

0.09

0 (0,2.01)

41/1090

45/918

0.22

0.76
(0.48,1.2)

not tested
0/1082

0/738

1

not tested
25/1044

19/866

0.88

1.07 (0.9,1.28)

300/1046

276/866

0.13

0.338

1.5 (0.58,3.27)

8/1084

2/738

0.22

1439/9358

1.35E-03

1.41
(1.14,1.73)

169/1090

146/918

0.81

1/618

0/9358

0.062

Inf (0.39,Inf)

0/1074

0/738

1

G/T

6/618

40/9358

0.063

3/1078

2/738

1

D1192E

T/G

102/618

1282/9358

0.054

144/1074

132/906

0.47

SETX

F1152C

G/T

27/618

317/9358

0.209

1.3 (0.84,1.95)

32/1042

32/866

0.52

9:135203632

SETX

T1118K

A/C

1/618

0/9358

0.062

Inf (0.39,Inf)

rs149546633

9:135204004

SETX

D994G

G/A

1/618

0/9358

0.062

Inf (0.39,Inf)

rs61742937

9:135204010

SETX

K992R

G/A

19/618

156/9358

0.016

rs376022544

9:135204235

SETX

M917T

C/T

1/618

1/9358

0.12

rs882709

9:135205006

SETX

A660G

G/C

67/618

548/9358

3.97E-06

rs139200312

9:135205116

SETX

E623D

C/A

1/618

3/9358

0.226

90

2.28
(0.79,5.45)
1.25
(0.99,1.56)

1.87
(1.09,3.05)
15.15
(0.19,1177.85)
1.95
(1.47,2.56)
5.05
(0.1,63.11)

0 (0,Inf)

1.09
(0.57,2.12)
0.86
(0.7,1.05)
2.74
(0.54,26.51)
0.97
(0.76,1.25)
0 (0,Inf)
1.03
(0.12,12.33)
0.91
(0.7,1.18)
0.83
(0.49,1.41)

not tested – singleton in ALS
0/1046

0/868

1

0 (0,Inf)

21/1090

11/916

0.22

1.62
(0.74,3.73)

0/1044

0/868

1

0 (0,Inf)

59/1082

51/912

0.92

0.97
(0.65,1.46)

not tested

rs200614765

9:135205594

SETX

S464L

T/C

1/618

6/9358

0.361

2.53
(0.05,20.86)

Novel

9:135206694

SETX

E327V

T/A

1/618

0/9358

0.062

Inf (0.39,Inf)

not tested – singleton in ALS

rs372193033

9:135206706

SETX

S323N

A/G

2/618

1/9358

0.011

30.36
(1.58,1768.42)

not tested

Novel

9:135210013

SETX

M274V

G/A

1/618

0/9358

0.062

Inf (0.39,Inf)

not tested – singleton in ALS

Novel

9:135211743

SETX

K220Q

C/A

1/618

0/9358

0.062

Inf (0.39,Inf)

not tested – singleton in ALS

Novel

9:135211898

SETX

R168Q

A/G

1/618

0/9358

0.062

Inf (0.39,Inf)

not tested – singleton in ALS

rs145438764

9:135218103

SETX

L158V

G/T

1/618

48/9358

0.369

0.31
(0.01,1.84)

9/1080

4/738

0.58

rs79740039

9:135224757

SETX

R20H

A/G

4/618

101/9358

0.415

0.6 (0.16,1.58)

9/1090

10/918

0.65

Novel

9:135224775

SETX

T14I

T/C

1/618

0/9358

0.062

Inf (0.39,Inf)

not tested – singleton in ALS

rs11258194

10:13152400

OPTN

M98K

A/T

15/618

297/9358

0.341

0.76
(0.42,1.28)

not tested

Novel

10:13160964

OPTN

Q235*

T/C

1/618

0/9358

0.062

Inf (0.39,Inf)

not tested – singleton in ALS

rs142812715

10:13166053

OPTN

Q314L

T/A

1/618

3/9358

0.226

5.05
(0.1,63.11)

not tested

rs4262766

12:109294259

DAO

G331E

A/G

1/618

0/9358

0.062

Inf (0.39,Inf)

not tested – singleton in ALS

rs121909536

14:21161845

ANG

K41I

T/A

1/618

23/9358

1

rs186547381

16:31201719

FUS

P431L

T/C

1/618

2/9358

0.175

rs201772423

16:31202343

FUS

R485W

T/C

1/618

1/9358

0.12

Novel

16:31202752

FUS

P525L

T/C

1/618

0/9358

0.062

Inf (0.39,Inf)

not tested – singleton in ALS

rs140268553

17:34171358

TAF15

R388H

A/G

1/618

7/9358

0.401

2.16
(0.05,16.89)

not tested

rs200175347

17:34171525

TAF15

R408C

T/C

1/618

2/9358

0.175

7.58
(0.13,145.89)

91

0.66
(0.02,4.07)
7.58
(0.13,145.89)
15.15
(0.19,1177.35)

0/1000

4/1046

1/824

2/868

0.45

0.7

0 (0,32.14)

1.54
(0.43,6.88)
0.76
(0.27,2.08)

1.66
(0.24,18.4)

not tested
not tested

0/1048

0/866

1

0 (0,Inf)

rs146459055

20:57014075

VAPB

D130E

G/T

1/618

11/9358

0.536

1.38 (0.03,9.5)

rs143144050

20:57016076

VAPB

M170I

A/G

5/618

18/9358

0.012

4.23
(1.22,11.88)

rs121912442

21:33032096

SOD1

A5V

T/C

1/618

0/9358

0.062

Inf (0.39,Inf)

not tested – singleton in ALS

Novel

21:33039600

SOD1

A90V

T/C

1/618

0/9358

0.062

Inf (0.39,Inf)

not tested – singleton in ALS

rs80265967

21:33039603

SOD1

D91A

C/A

2/618

9/9358

0.146

rs121912441

21:33039672

SOD1

I114T

C/T

1/618

1/9358

0.12

rs144503053

22:29682919

EWSR1

S203T

A/T

1/618

1/9358

0.12

Novel

22:29682932

EWSR1

T207S

G/C

1/618

0/9358

0.062

Inf (0.39,Inf)

rs41311143

22:29693915

EWSR1

G470S

A/G

24/618

119/9358

6.70E-06

3.14
(1.92,4.94)

92

3.37
(0.35,16.35)
15.15
(0.19,1177.85)
15.15
(0.19,1177.35)

not tested
3/1088

2/916

1

1.26
(0.14,15.15)

not tested
not tested
1/1076

0/906

1

Inf (0.02,Inf)

not tested – singleton in ALS
12/1086

13/916

0.55

0.78
(0.32,1.86)
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Chapter 4
Risk Haplotype of the C9ORF72 Locus
4.1 Abstract
The most common genetic cause of ALS to date is the hexanucleotide repeat expansion in
the gene C9ORF72. The presence of a common haplotype, tagged by rs3849942, shared between
all expansion carriers led to the hypothesis of an expansion founder event, however the shared
haplotype could alternatively be a genetic background that is permissive to expansion. We found
that all subjects in our cohort of 153 expansion carriers shared at least part of the common
haplotype. Sequencing a BAC containing C9ORF72 locus identified the rare SNP rs147599399
within the risk haplotype that was not shared between all expansion carriers and was also present
in the general population. Additionally, survival in expansion carriers with the minor allele at
rs147599399 was roughly 20 months longer than expansion carriers that were homozygous for
the reference allele (p=0.00047). These results show that both rs3849942 and rs147599399 are
potential cis-modifiers of the expansion with rs3849942 promoting the formation of C9ORF72
repeat expansions and rs147599399 mediating their effects. A genetic background that is
permissive to expansions raises that possibility that expansions can arise de novo and would
account for the prevalence of the expansion in sporadic cases of ALS. Understanding how the
genetic background promotes expansion could allow us to create strategies to intervene and
prevent repeats from expanding.

4.2 Introduction
Hexanucleotide (GGGGCC) repeat expansions in the C9ORF72 gene are the most
common cause of both familial and sporadic ALS to date.1,2 They account for approximately
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34% of familial cases and 6% of sporadic cases overall with frequencies varying by population.
The expansion is most prevalent in ALS subjects in Sweden and Finland and lowest in Asian
populations (reviewed in Van Blitterswijk et al.)3 C9ORF72 repeat expansions also account for a
significant portion of frontotemporal dementia (FTD) and have been found in other neurological
disorders. While the pathogenic range of repeat expansions has yet to be clearly delineated,
expansions larger than 26 are very rare in normal controls.1,2,4,5
The repeat expansion is thought to have arisen from a single founder event in the
Scandanavian population.1,2,5–9 A 42-SNP haplotype spanning 232 kb was identified in a GWAS
of Finnish SALS subjects with the A allele of rs3849942 tagging the haplotype.10,11 With the
discovery of the C9ORF72 repeat expansion, it was shown that all expansion carriers shared the
rs3849942 risk allele1. Analysis of the entire risk haplotype in wider populations revealed that all
expansion carriers possessed at least part of the risk haplotype.8 The prevalence of the C9ORF72
expansion is lowest in Asian populations with have the least amount of Scandanavian
admixture.3
This observation has been widely interpreted to mean that the expansion arose once
approximately 1500 years ago. The alternative hypothesis to this single founder event is that the
risk haplotype is a genetic background that is permissive to expansion. Multiple studies have
shown that the rs3849942 A allele is associated with longer repeat lengths in those without the
full expansion.1,5,12 It is possible that these are pre-mutations that can expand further into a
pathogenic range. The risk haplotype is at lower frequencies in Asian populations5 and therefore
C9ORF72 repeat expansions would be less likely to occur in these populations. Two other
studies have provided evidence of multiple origins of the expansions. Beck et al. used
microsattelite markers to show that expansions carriers in the UK did not share recent common
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ancestry12 and Fratta et al used Southern blotting to show an individual with a small expansion in
blood but a large expansion in brain.13
Evidence of multiple origins of the expansion raises the possibility that expansions can
arise de novo on the risk haplotype and would explain the prevalence of C9ORF72 expansions in
sporadic disease. This would also have implications for estimating the risk of ALS for genetic
counseling. Furthermore evidence of multiple expansions would indicate that the risk haplotype
is permissive to expansion and allow us to identify the cis-acting modification that promotes
repeat expansions in C9ORF72.
In this study we first investigated the known risk haplotype in our cohort of expansion
carriers to determine if there were alternate genetic backgrounds that would support multiple
origins of expansion. In addition we reasoned that rare variation would be more informative with
regards to the recent history of the expansion, therefore we use a BAC containing the C9ORF72
locus derived from a patient carrying the full expansion to identify rare variants within the risk
haplotype.

4.3 Methods
4.3.1 Subjects
This study used a total of 153 subjects that carried full C9ORF72 repeat expansion as
diagnosed by repeat-primed PCR. The clinical diagnoses of the subjects were 67 SALS, 67
FALS from 48 families (including asymptomatic relatives), 14 Alzheimer’s disease (AD), and 5
unaffected controls. We also included 57 intermediate-length (19-30 repeats) expansion carriers
(SALS=7, AD=40, Parkinson’s disease=7, Controls=3). Of the 141 ALS subjects, 42 were from
Coriell panels NDPT026, NDPT100, NDPT103, NDPT106, and NDPT116. The remaining ALS
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subjects were collected at the Washington University Neuromuscular Disease Center in St.
Louis, Missouri (WUSM), the Virginia Mason Medical Center (VMMC), or Houston Methodist
Hospital.

4.3.2 Genotyping
Eight SNPs from the known risk haplotype rs1110264, rs2225389, rs2589054,
rs10511816, rs4879515, rs868856, rs3849942, and rs2453556) were genotyped in 181 subjects
from 168 families using Sequenom. An additional 31 subjects were genotyped for
rs3849942 using a custom assay (KASPar; KBioscience). Genotyping of rs147599399 was
performed by PCR amplification with primers 5’ TCT TTA GCC TAG GTG GGG AGA 3’ and
5’ TGA CAT TTG TAG AGC ACA GCA 3’ and subsequent enzymatic digestion with BstN1.
This enzyme only cuts sequences that contain the alternate allele. rs147599399 was genotyped in
all ALS subjects and asymptomatic relatives that carried full expansions, 5 AD subjects with full
expansions, and Coriell panels NDPT026, NDPT100, NDPT103, NDPT106, and NDPT116, a
total of 567 subjects.

4.3.3 MiSeq
We obtained DNA from a BAC containing an insert spanning chr9:27527137-27683106
derived from a subject carrying a full repeat expansion confirmed by Southern blotting (Figure
4.1). We sequenced this BAC on the Illumina MiSeq (GTAC). The sequencing reads were
aligned to the Hg19 human genome using Novoalign and variants were called using Samtools.
We annotated variants using SeattleSeq and obtained variant frequencies from the 1000 genomes
phase 3 data.
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Figure 4.1 Southern blot confirmation of C9ORF72 repeat expansion in a BAC. The blue box indicates the clone
used for sequencing

4.3.4 Statistical analysis
All statistical tests were performed in R version 3.1.1. Comparisons of allelic frequencies
were done using Fisher’s exact test. Association with age of onset was tested using Wilcoxon
rank-sum test. Association with gender and site of onset were tested using Fisher’s exact tests.
Survival analysis was performed using the Survival package to create Kaplan-Meier curves and
Cox-proportional hazards models.

4.4 Results
4.4.1 Known risk haplotype
The 8 SNPs from the known risk haplotype were genotyped in 167 subjects in total. We
included subjects that carried the full expansion (n=110) as well as intermediate length
expansions (n=57). Confirming the findings in other populations, all subjects carried at least part
of the risk haplotype (Figure 4.2 and Figure 4.3). There were 3 subjects that were homozygous
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for the non-risk allele at the tag-SNP rs3849942, two of which were intermediate-length
expansion carriers. The full expansion carrier was of African American ancestry. In all three
cases with the non-risk allele at the tag SNP, both the upstream and downstream SNPs were risk
alleles.
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Figure 4.2 Largest continuous risk haplotype in patients with full C9ORF72 repeat expansions. The green line
represents the recombination rate. The vertical purple line represents the location of the repeat expansion. Each row
represents a single individual and a blue square indicates the subject carried the risk allele at that SNP.
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Figure 4.3 Largest continuous risk haplotype with intermediate-length C9ORF72 repeat expansions (19-30 repeats).
The green line represents the recombination rate. The vertical purple line represents the location of the repeat
expansion. Each row represents a single individual and a blue square indicates the subject carried the risk allele at
that SNP.
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4.4.2 Rare SNPs identified by MiSeq
In order to determine if there were rare variants within the risk haplotype that would give
us additional insight into the origins of the repeat expansion, we sequenced a BAC containing the
section of the hapltyope nearest to the repeat and spanning rs3849942. There were 4 variants
within the range of the risk haplotype (Table 4.1). All variants were confirmed by sequencing
and all are on the same haplotype as the expansion since they were discovered in the BAC.
Interestingly, none of these was novel to this individual. We focused on rs147599399 because of
its proximity to the tag SNP rs3849942 (600bp away), because this SNP is very rare in the
subjects included in phase 3 of the 1000genomes project, and because it is not present in the
Finnish population where the expansion is thought to have arisen (Table 4.2).
Table 4.1 Rare variants on the C9ORF72 risk haplotype discovered by MiSeq. *Denotes subject used to create BAC.

Position

dbSNP ID

Ref
allele

Alt
allele

MAF(%)
1000genomes
phase3

BAC
genotype

Affected
Carrier*

Affected
Carrier

Unaffected
Carrier

chr9:27543629

rs147599399

A

G

0.339

G/G

G/A

G/A

G/A

chr9:27601617

rs75747155

G

A

0.778

A/A

G/A

G/A

G/A

chr9:27617365

rs79652154

C

A

0.572

A/A

C/A

C/A

C/A

chr9:27673058

rs138129614

A

G

0.179

G/G

A/G

A/G

A/G

4.4.3 Prevalence of rs147599399 in additional expansion carriers
We genotyped rs147599399 in a total of 106 full expansion carriers from 86 families,
including the family in which the variant was originally identified (WUNM0026). There was
one family in addition to WUNM0026 that carried the variant; all expansion carriers were also
heterozygous for rs147599399 in both families confirming the SNP is in phase with the
C9ORF72 repeat expansion. A total of 19 out of the 86 families carried the variant resulting in a
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minor allele frequency of 11%. This is dramatically increased compared to 0.339% in all
subjects included in 1000genomes phase3 (p<2.2X10-16, OR=35.9, 95%CI=17.5-76.2). The vast
majority of expansion carriers in our cohort are of European ancestry so we also compared only
those of white, non-Hispanic ethnicity to 1000 genomes subjects with European ancestry
(p=1.625x10-10, OR=12.8, 95%CI=5.5-31.5). Because our study included expansion carriers of
mixed phenotypes, we also looked at rs147599399 in AD. Five of the 87 families had
Alzheimer’s disease, one of which had the rs147599399 G allele.
To validate this finding, we genotyped rs147599399 in 460 ALS samples from Coriell.
The G allele was found in 6/35 expansion carriers compared to 16/425 non-expanded ALS
subjects (p=0.004, OR=4.87, 95%CI=1.5-13.7). The frequency of rs147599399 in non-expanded
ALS was higher than in the total 1000 genomes cohort (p=3.46x10-6), but not higher than in the
1000 genomes subjects of European ancestry (p=0.116)
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Table 4.2 Frequency of rs147599399 in all 1000 genomes populations
Population

Allele count

MAF (%)

Tosaini in Italy (TSI)

209 (A) / 5 (G)

2.336

Colombian in Medellin, Colombia (CLM)

185 (A) / 3 (G)

1.596

Iberian in Spain (IBS)

211 (A) / 3 (G)

1.402

British in England and Scotland (GBR)

180 (A) / 2 (G)

1.099

Americans of African Ancestry in SW USA (ASW)

121 (A) / 1 (G)

0.82

African Caribbeans in Barbados (ACB)

191 (A) / 1 (G)

0.521

Punjabi from Lahore, Pakistan (PJL)

191 (A) / 1 (G)

0.521

Puerto Ricans from Puerto Rico (PUR)

207 (A) / 1 (G)

0.481

Bengali from Bangladesh (BEB)

172 (A)

0

Chinese Dai in Xishuangbanna, China (CDX)
Utah Residents (CEPH) with Northern and Western European Ancestry
(CEU)
Han Chinese in Beijing, China (CHB)

186 (A)

0

198 (A)

0

206 (A)

0

Southern Han Chinese in China (CHS)

210 (A)

0

Esan in Nigeria (ESN)

198 (A)

0

Finnish in Finland (FIN)

198 (A)

0

Gujarati Indian from Houston, Texas (GIH)

206 (A)

0

Gambian in Western Divisions in the Gambia (GWD)

226 (A)

0

Indian Telugu from the UK (ITU)

204 (A)

0

Japanese in Tokyo, Japan (JPT)

208 (A)

0

Kinh in Ho Chi Minh City, Vietnam (KHV)

198 (A)

0

Luhya in Webuye, Kenya (LWK)

198 (A)

0

Mende in Sierra Leone (MSL)

170 (A)

0

Mexican ancestry in Los Angeles (MXL)

128 (A)

0

Peruvian in Lima, Peru (PEL)

170 (A)

0

Sri Lankan Tamil from the UK (STU)

204 (A)

0

Yoruba in Ibadan, Nigeria (YRI)

216 (A)

0

4991 (A) / 17 (G)

0.339

ALL

4.4.4 Association of rs147599399 with clinical characteristics in ALS
Within our ALS expansion carriers, there were no differences between gender, site of
onset, or age of onset with A/A versus A/G genotypes at rs147599399. However, there was a
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difference in survival with the A/G individuals having longer survival (median=50 months) than
A/A individuals (median=32) (figure 4.3). We fit a cox-proportional hazards model controlling
for age of onset and found that rs147599399 was significantly associated with survival (hazard
ratio (A/G vs A/A =0.235, p=0.00047) with the G allele associated with longer survival. There
was no difference in survival by rs147599399 genotype in non-expansion carriers.
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Figure 4.4 Survival curves by rs147599399 genotypes.

4.5 Discussion
Analysis of the C9ORF72 locus has shown that there is a common haplotype shared
between expansion carriers. The simplest explanation for this is observation is a single founder
expansion event. Here we provide direct evidence of multiple expansion events based on the
SNP rs147599399. This SNP is present in both non-expansion carriers and expansion carriers,
but is not present in all expansion carriers. It is less likely that the SNP arose in both groups than
the expansion arising on both backgrounds, especially given the known instability of the
repeat.12–14 Since the rs147599399-G carriers in the phased 1000 genomes data have the risk
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allele both upstream and downstream of the repeat on the same chromosome, it is also unlikely
that a recombination event between rs147599399 and the repeat in an expansion carrier led to the
rs147599399-G allele in non-expansion carriers.
An alternate possibility is that there was a founder pre-mutation on the originally
identified risk haplotype that is more likely to continue to expand into a pathogenic range as is
the case with Myotonic Dystrophy type 115,16 and Friedreich Ataxia.17 In this scenario, the
rs147599399 SNP would have occurred on the pre-mutation background and a subset of these
would pass on full expansions to their offspring and a subset would remain in the pre-mutation
range and not develop disease (Figure 4.5). Further analysis of transmission of intermediatelength alleles will be required to determine if this is a possibility.

Figure 4.5 Models of expansion events
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In addition to showing multiple origins of the expansion, we have discovered that
rs147599399 modifies survival in expansion carriers with the G allele resulting in an almost 20
month increase in disease duration. rs147599399 does not influence survival in ALS patients
without the repeat expansion, suggesting that the SNP exerts an effect specifically on the repeat
expansion. It could be acting by stabilizing the expansion, altering transcription of C9ORF72, or
altering translation of dipeptide-repeats.18 This is another in a growing list of genetic factors that
have been shown to modify the disease phenotype in C9ORF72-associated disease along with
TMEM106B19,20, ATXN221, and several others.22 However, to our knowledge, this is the first
modifier in cis with the expansion.
This is not the first evidence of cis-acting genetic factors influencing repeat expansions.
Haplotype is an important factor in Huntington Disease (HD) with multiple origins of the
expansion arising on population-specific haplotypes, but the exact mechanism of this is not
known.23–27 Possibilities include changes in replication origins which can alter stability of repeats
during replication,28,29 and formation of secondary structures, which can in turn alter the effects
of DNA mismatch repair machinery.30 Methylation of flanking sequences can also alter stability
of repeats as in SCA731 and fragile-X syndrome.32
We show here that genetic context is an important factor in the pathogenicity of
C9ORF72 through both the risk background associated with rs3849942 and the increased
survival associated with rs147599399. This finding suggests that de novo expansions on the
permissive haplotype are possible, which might explain why the expansion is relatively common
in sporadic ALS patients. Understanding the mechanisms behind these phenomena will allow us
to develop strategies to intervene.
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Chapter 5
Characterization of size and stability of C9ORF72 repeat
expansions
5.1 Abstract
Despite the prevalence of C9ORF72 repeat expansions in ALS, little is known about the
importance of repeat sizes and stability. Understanding these characteristics can have a great
impact in our knowledge of the pathogenic mechanisms of the repeat expansion and of how it is
transmitted from generation to generation. We used Southern blot analysis to determine size of
the repeat expansion in a variety of patient tissues. We observed a high degree of somatic
instability between tissues with larger expansions in most regions of the brain than in blood.
Expansions size did not correlate with clinical characteristics in any tissue and there was no
difference in expansion size in blood between affected and unaffected expansion carriers. There
was instability in transmission of expansions within families, but unlike the transmissions in
repeat disorders with anticipation, the expansions showed increases and decreases between
generations. It will be important to continue this work with additional samples in order to
perform more concrete analysis.

5.2 Introduction
Large expansions in C9ORF72 are the most common cause of ALS, however the effects
of expansion sizes on pathogenesis are not well understood.1,2 Many pathogenic mechanisms of
C9ORF72 repeats have been proposed which could be influenced by expansion sizes. GGGGCC
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repeats form RNA-DNA heteroduplexes called G-quadruplexes3,4 and increases in repeat number
altered G-quadruplex conformation in small repeats.5 Expanded C9ORF72 also forms nuclear
RNA foci which sequester RNA-binding proteins.1,6–8 Expression of constructs with 8,38, or 72
repeats in cell lines and zebrafish showed length dependent effects on the formation of RNA
foci, especially in neuronal cells.9 The role of repeat length in repeat-associated non-ATG
initiated translation into aggregating dipeptide repeats10–13 has not been investigated, but it is
possible that larger expansions would promote increased production of dipeptides and increased
aggregation in a similar fashion to RNA foci.
Variability in expansion size and stability could explain disease characteristics such as
tissue specificity, progressive degeneration, and incomplete penetrance. For example, in the
related repeat expansion disorder Myotonic Dystrophy (DM), somatic instability has been
observed in the CTG repeat tract of DMPK with larger repeats in muscle (the affected tissue)
compared to blood.14 Additionally the repeat is unstable and continues to expand with age
accounting for the progressive nature of the disease.15 Like many other repeat expansion
disorders DM1 also shows anticipation with larger repeat expansions and earlier onset in
progressive generations.16,17
C9ORF72 expansions are detected by repeat-primed PCR (RP-PCR) which does not size
expansions larger than 30 repeats, therefore Southern blots must be used to detect the number of
repeats in full expansions. Due to the difficulty of performing Southern blots, very few studies
have been done observing the impact of expansion sizes, most of which have focused on
expansions in blood-derived DNA.1,18–24 All studies have shown expansion sizes of hundreds to
thousands of repeats in all tissues and variability of expansion sizes between tissues. Although
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some studies have reported clinical associations with expansion sizes in certain tissues, these
results are mostly inconsistent between studies.18,19,23
In this study, we use Southern blot analysis to determine expansion lengths in multiple
tissue types in a cohort of ALS subjects. In addition, we analyze the stability of repeat
expansions both in cell culture and in transmission in families.

5.3 Methods
5.3.1 Samples
All patients included in this study were diagnosed with definite or probable ALS at either
Washington University Neuromuscular Disease Center in St. Louis, Missouri (WUSM) or the
Virginia Mason Medical Center (VMMC). Patients were screened for C9ORF72 repeat
expansion by repeat-primed PCR as previously described (Figure 5.1).1 DNA from patient
samples was prepared by the Hope Center DNA/RNA purification core at Washington
University in St. Louis. All participants had provided signed informed consent for studies
approved by local institutional review boards.

Expanded Repeat

Normal

Fragment Size (bp)

Figure 5.1 Example of repeat-primed PCR to detect C9ORF72 repeat expansions

117

5.3.2 Southern blots
Southern blots were performed as previously described.25 Briefly, genomic DNA was
digested using either XbaI or XbaI and TaqαI. 3.5-5ug of digested DNA was run out on a gel and
transferred to the membrane. Hybridization was performed using a 590bp probe labeled with 32P
that hybridizes adjacent to the repeat. Blots were exposed on film for 1-7 overnights. Band sizes
were determined using GelAnalyzer (ww.gelanalyzer.com). Either the 1kb plus DNA ladder
(Invitrogen) or the 1kb DNA ladder (NEB) was used as a standard to measure expansion size.
The maximum, minimum and peak for each band were measured. The number of repeats was
calculated by subtracting the digest size of 0 repeats (2359 for XbaI digest or 1941 for
XbaI+TaqαI) from the measured band size and dividing by 6.

5.3.3 Statistical Analysis
All statistical analyses were performed in R v3.1.3. For samples that had multiple
expansion size, the largest was used in analysis. When samples were blotted more than once, the
average was used. Differences in number of repeats between affected and unaffected expansion
carriers and between different tissues were assessed by Wilcoxon-rank sum tests. Differences in
number of repeats in different tissues within individuals were assessed using Wilcoxon paired
signed -rank tests. Correlations between repeat sizes and age of onset and between repeat sizes
from different tissues were performed using Spearman correlations Survival was assessed using
cox-proportional hazards models controlling for age of onset.

5.4 Results
5.4.1 Expansions in blood-derived DNA
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We were able to perform Southern blots on blood-derived DNA from 39 different
expansion carriers. Expansions in blood-derived DNA generally showed long smears on
Southern blots (Figure 5.2). The median size of the smear peaks was 1702 and ranged from 705
to 3520 repeats. Smear minima were between 477 and 2297 repeats with a median of 967. Smear
maxima ranged from 840 to 3947 repeats.

Figure 5.2 Representative Southern blots of blood-derived DNA. Sample numbers are listed above. The far right sample is an
ALS patient that was negative for the expansion by RP-PCR and is shown as a negative control. Samples were digested with
XbaI resulting in wild-type alleles of ~2359bp.

There was no difference in the minima (p=0.56), maxima (p=0.41) or peaks (p=0.33) between
the 26 symptomatic and 13 asymptomatic expansion carriers (peaks shown in figure 5.3 A).
There was also no correlation between repeat size and age of onset in symptomatic repeat
carriers (p=0.60 for minima, p=0.56 for maxima, p=0.94 for peaks [shown in Figure 5.3B]).
Number of repeats also had no effect on survival (p=0.43, p=0.39, p=0.95 for peaks, maxima,
and minima respectively).
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Figure 5.3 Relationship between C9ORF72 repeat sizes and phenotype. A. Boxplot of peak number of repeats in blood-derived
DNA in affected and unaffected expansion carriers. The data are transposed on top of the boxplot. B. Scatterplot of peak number
of repeats in bood-derived DNA versus age of onset. The blue line represents the least-squares regression line.

5.4.2 Expansion sizes across families
Blood derived DNA was available from 7 families with multiple expansion carriers.
Three families had multiple causes of disease. Family WUNM0026 (Figure 5.4 A) included one
distant affected relative that tested negative for the expansion, but was found to be a
heterozygous carrier of the SOD1 p. D91A variant. This individual had another affected cousin
who was positive for the expansion. Southern blotting of this family confirmed the absence of
the expansion in the p.D91A carrier and presence of the expansion in the other affected
members. In family WUNM0085 the proband was positive for the expansion and their distant
relative who also had ALS tested negative and was confirmed by Southern blot (Figure 5.4 D).
The cause of disease is still unknown in this individual. In family WUNM0194 (Figure 5.4 G)
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the proband and two unaffected sisters carried the expansion. They had one affected brother who
was negative for the expansion and whose cause of disease is unknown.
We observed both stable and unstable transmission patterns in families. The expansion
was roughly the same size in all expansion carriers in families WUNM0026, WUNM0160,
WUNM0226, WUNM0521, and WUNM0194 (Figure 5.4 A, B, C, E, G). Family WUNM0176
(Figure 5.4 F) has a proband whose daughter, mother, and brother are all asymptomatic and all
have different sized repeats. In fact the proband has the smallest repeat out of the four family
members.
There was no relationship between expansion size and whether or not the carrier was
symptomaticwhich is consistent with the statistical analysis performed above (which includes
these families). Four families (WUNM0026, WUNM0226, WUNM0512, WUNM0194) all had
affected and unaffected individuals with expansions of roughly the same size. In family
WUNM0226, both expansion carriers were identical twins but only one had ALS. In family
WUNM0176 the proband had a smaller repeat than three asymptomatic carriers.
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A

B

E

C

F

D

G

Figure 5.4 Southern blots of blood-derived DNA from 7 ALS families. Samples were digested with XbaI resulting in wild-type
alleles of ~2359b.p A.WUNM0026, B. WUNM0160, C. WUNM0226, D. WUNM0085, E. WUNM0521, F. WUNM0176, G.
WUNM0194
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5.4.3 Expansions in cultured cells
To observe how C9ORF72 repeat expansions behave in cultured cells, we performed
Southern blots on fibroblast-derived DNA from 19 expansion carriers, all of whom were
symptomatic. Expansions in fibroblasts were uniformly smaller than blood-derived DNA and
peak sizes ranged from 340-960 repeats (Figures 5.5 and 5.6A) with the exception of one sample
with a small expansion of ~35 repeats. The median peak number of repeats was 703. Some
fibroblast lines showed multiple sizes of expansions (Figure 5.6A). Unsurprisingly, due to the
narrow range of expansion sizes in fibroblasts, there was no correlation between number of
repeats in fibroblast-derived DNA and age of onset. There were also no associations between
number of repeats and survival (p=0.16, p=0.17, p=0.09 for minima, peaks, and maxima
respectively).

Figure 5.5 Peak expansion sizes in fibroblast-derived DNA
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Subject 32 showed multiple expansion sizes in fibroblast-derived DNA (Figure 5.6 A)
that were both smaller than the single band observed in the blood-derived DNA from the same
patient (Figure 5.6 A). There was no correlation between peak expansion size in fibroblastderived DNA and peak expansion size in blood-derived DNA (data not shown). There were no
significant correlations between peak, maximum, or minimum number of repeats in fibroblastderived and blood-derived DNA.
We performed Southern blots of fibroblasts at different passages to observe changes in
expansion size through cell divisions. The expansion was larger in later passages in two different
cell lines (Figure 5.6 B). We also performed Southern blots of a lymphoblast cell line from
patient ND08980 from the Coriell repository (Figure 5.6 C). This cell line showed multiple
expansion sizes and was also unstable with the latest passage (p17) only showing one expansion
size.

A

B

C

Figure 5.6 Southern blots of cultured cells. Samples were digested with XbaI resulting in wild-type alleles of ~2359bp. A.
Representative blot of cultured patient fibroblast-derived DNA. B. Fibroblast-derived DNA from two patients at passages 6 and
13. C. Lymphoblast-derived DNA from one patient at passages 9, 11, and 17
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5.4.4 Expansions in different tissues
Next we used tissue from patient autopsies to observe somatic instability of the repeat
expansion. In initial studies we noted that expansions in brain derived DNA were larger than in
blood and fibroblasts from the same individual (Figure 5.7), so we expanded our analysis to a
range of tissues across the entire body and multiple regions of the CNS.

Figure 5.7 Expansions in blood, brain and fibroblast derived DNA from a single individual (patient 18). Sample were digested
with XbaI resulting in wild-type alleles of ~2359bp.

We observed variability in expansion size across tissue samples from the same patients
(Figure 5.8). The most obvious pattern was that expansions in DNA from the cerebellum are
smaller than other brain regions (seen in Figure 5.8A). This was consistent across all individuals.
Another interesting finding was that expansions in non-CNS tissues are within the same size
range as CNS tissues. In fact it appears that expansions in the kidney are in fact larger than in
multiple brain regions (Figure 5.9). Expansions in DNA derived from the testes was also very
large, although they also showed a significant amount of DNA that did not migrate out of the
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wells of the gel. It is unclear if this is DNA that has very large expansions or if it is simply less
soluble.

Figure 5.8 Southern blots across multiple tissues. Samples were digested with XbaI+TaqαI resulting in wild-type alleles of
~1941bp. A. Patient 47, B. Patient 68

We compared number of repeats across different tissue types for which there were at least
three subjects with usable measurements. This included cerebellum (n=6, median =1570,
range=996-1761), frontal cortex (n=4, median=2317, range=1588-2413), occipital cortex (n=5,
median=2088, range=1290-3375), sensory cortex (n=3, median=2391, range= 2145-2524),
motor cortex (n=6, median=2334, range=1447-2716), cervical spine (n=4, median=2171,
range=1290-3677), lumbar spine (n=4, median=2326, range=1930-3615), kidney (n=3,
median=2951, range=2187-4296), and blood (n=39, median=1702, range=705-3520). Each
tissue was compared to all of the others and we found that expansions in the cerebellum were on
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average smaller than in frontal cortex, sensory cortex, lumbar spine, and kidney. No other
comparisons were statistically significant (Table 5.1). We also performed paired tests comparing
the differences in expansion sizes between tissue types within individuals. None of these
comparisons were significant (Table 5.2). There were also no significant correlations between
expansion size in a given tissue and expansion size in any other tissue (data not shown).

Figure 5.9 Repeat sizes across multiple tissues. Only tissues with at least three subjects blotted were included
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Table 5.1 P-values from Wilcoxon rank-sum test comparing expansion sizes in different tissue types. Only peak repeat numbers
were used.

Cerebellum

Cervical
Spine

Motor
Cortex

Occipital
Cortex

Frontal
Cortex

Kidney

Lumbar
Spine

Sensory
Cortex

Blood

-

-

-

-

-

-

-

-

-

0.1714

-

-

-

-

-

-

-

-

0.1320

1.0000

-

-

-

-

-

-

-

0.3290

0.8057

0.5368

-

-

-

-

-

-

0.0381

0.8857

0.9143

0.9048

-

-

-

-

-

Kidney
Lumbar
Spine
Sensory
Cortex

0.0238

0.4000

0.1667

0.2500

0.4000

-

-

-

-

0.0095

0.8857

0.7619

0.5556

0.8857

0.6286

-

-

-

0.0238

0.8571

1.0000

0.5714

0.6286

0.4000

0.8571

-

-

Blood

0.4133

0.2502

0.1287

0.3180

0.2333

0.0191

0.0689

0.0873

-

Cerebellum
Cervical
Spine
Motor
Cortex
Occipital
Cortex
Frontal
Cortex

Table 5.2 P-values from Wilcoxon paired signed rank tests comparing expansion sizes in different tissue types within individuals.
Only peak number of repeats were used

Cerebellum
Cervical
Spine
Motor
Cortex
Occipital
Cortex
Frontal
Cortex
Kidney
Lumbar
Spine
Sensory
Cortex
Blood

Cerebellum

Cervical
Spine

Motor
Cortex

Occipital
Cortex

Frontal
Cortex

Kidney

Lumbar
Spine

Sensory
Cortex

Blood

-

-

-

-

-

-

-

-

-

0.375

-

-

-

-

-

-

-

-

0.0625

0.875

-

-

-

-

-

-

-

0.25

1

0.625

-

-

-

-

-

-

0.125

0.5

0.25

0.25

-

-

-

-

-

0.25

0.5

0.25

0.5

0.5

-

-

-

-

0.125

0.75

0.875

1

0.75

0.25

-

-

-

0.25

1

0.25

1

0.5

0.5

0.25

-

-

1

0.25

0.125

0.125

0.5

0.25

0.25

0.5

-

We analyzed the relationship between expansion size in different tissue regions and
clinical course (Table 5.3). There was a moderate association that was not statistically significant
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between age of onset and expansion size in the sensory cortex, however there were only three
observations for this tissue.
Table 5.3 Associations between expansion sizes in different tissues and clinical presentation. P-values from spearman correlation
and cox-proportional hazards models are given for associations with age of onset and survival respectively.

Cerebellum
Cervical
Spine
Motor Cortex
Occipital
Cortex
Frontal
Cortex
Kidney
Lumbar Spine
Sensory
Cortex

Age of
onset
0.8569

Survival
0.27

0.6428
0.4441

0.5
0.5

0.9779

0.27

0.5549
0.7727
0.8416

1
1
0.55

0.0611

1

5.5 Discussion
Based on characteristics of other repeat expansion disorders and the relative lack of
knowledge regarding characteristics of repeat expansions, we investigated these characteristics
of the C9ORF72 repeat expansion in our ALS cohort. We found all repeat expansions to be very
large, ranging from ~700 repeats to ~4500 repeats, and showing a high degree of instability.
Within patients, expansion size varied with the smallest expansions in the cerebellum (not
including cultured fibroblasts). There were no significant differences between different CNS
regions or between CNS and non-CNS tissues (blood and kidney). The same pattern of smaller
repeats in the cerebellum compared to other brain regions has been observed in all studies
comparing C9ORF72 expansions across brain regions.18,22,23
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We did observe instability of the repeat during transmission within families. Unlike
repeat expansion disorders with anticipation, in which expansions become larger with each
subsequent generation, we saw both families with increases or decreases in expansion size and
families with no change in expansion size from parents to offspring. One family in fact showed a
decrease in size from an unaffected parent to the affected proband and then an increase in size
from the proband to their daughter.
We saw no difference in expansion size in blood-derived DNA between symptomatic and
asymptomatic expansion carriers from ALS families. There was in fact a set of monozygotic
twins with identical repeat sizes that were discordant for disease. Another set of monozygotic
twins with C9ORF72 expansions that are discordant for disease has been reported as well.26 It is
possible that symptomatic expansion carriers have larger expansions in CNS tissues, however no
tissue from asymptomatic carriers was available for comparison.
Our analysis did not identify any associations between repeat length in any tissue and
either age of onset or survival. While other studies have reported associations, they have not
been consistent between studies. Beck et al.19 found smaller expansions in blood to be associated
with earlier age of onset, while others did not.18,23 van Blitterswijk et al18 found smaller repeats
in the frontal cortex were associated with earlier age of onset and larger repeats in cerebellum
were associated with shorter survival in patients with FTD. There were no associations in ALS.
Nordin et al. 23found smaller expansions in the cerebellum and parietal lobe to be associated with
earlier age at onset and larger expansions in the parietal lobe to be association with shorter
survival.
The lack of correlations with clinical characteristics in our study may be due to the small
sample-size. The technical difficulty and amount of sample required to perform Southern blots
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limited the number of usable observations for analysis. Additionally, the imprecise nature of
obtaining the number of repeats from Southern blot images decreases the accuracy of our
analysis. Size estimation of expansions larger than 20kb becomes even more inaccurate as there
small errors in measurement translate into large differences in estimated size. For these reasons,
the development of novel methods, such as single-molecule real-time sequencing of long reads
used to sequence expansions in FMR127, would be useful for continued study of this repeat
expansion.
One interpretation of these results is that the number of repeats does not determine
toxicity. It is possible that there is a threshold effect where expansions become toxic once they
reach a certain size and additional repeats do not have any added effect. The fact that we see no
difference in expansion sizes between affected and unaffected tissues points to a tissue specific
ability to cope with toxic repeat expansions. Furthermore, each tissue tested contains a
heterogeneous mix of cell types (neurons, microglia, astrocytes, etc.). It is possible that
differences will become more apparent if we look specifically at different types of neurons.
Additionally, the lack of difference in expansion size between unaffected carriers indicates that
additional genetic and environmental factors are involved in pathogenesis. Further studies of
repeat sizes in larger cohorts are needed to confirm these findings and to improve the analysis of
clinical characteristics.
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Chapter 6
Identification of mutations in the TREM family genes
The work presented in this chapter resulted in the following publication:
1. The TREM2 variant p.R47H is a risk factor for sporadic amyotrophic lateral sclerosis.
Cady J, Koval ED, Benitez BA, Zaidman C, Jockel-Balsarotti J, Allred P, Baloh RH,
Ravits J, Simpson E, Appel SH, Pestronk A, Goate AM, Miller TM, Cruchaga C, Harms
MB. JAMA Neurol. 2014 Apr;71(4):449-53. doi: 10.1001/jamaneurol.2013.6237

6.1 Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease in which
microglia play a significant and active role. Recently, a rare missense variant (p.R47H) in the
microglial activating gene TREM2 was found to increase the risk of several neurodegenerative
diseases, including Alzheimer’s disease. Here we show that the TREM2 variant p. R47H was
more common in subject with ALS than in controls and is therefore a significant risk factor for
ALS (OR=2.40; 95%CI=1.29-4.15; p=4.1x10-3). Furthermore, TREM2 expression was increased
in spinal cords from ALS patients and SOD1G93A mice (p=2.8x10-4, p=2.8x10-9 respectively),
confirming dysregulated TREM2 in disease. TREM2 expression in human spinal cord was
negatively correlated with survival (p=0.04), but not other phenotypic aspects of disease. This
study demonstrates that the TREM2 p.R47H variant is a potent risk factor for sporadic
amyotrophic lateral sclerosis. These findings identify the first genetic influence on neuroinflammation in ALS and highlight the TREM2 signaling pathway as a therapeutic target in ALS
and other neurodegenerative diseases.
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6.2 Introduction
Activated microglia in the vicinity of degenerating neurons are a long-recognized
pathological feature of ALS1, but whether such activation is a beneficial response or injurious
contributor to the disease process remains unclear. In fact the answer may be both- mouse model
data show that microglia express both neuroprotective and neurotoxic factors simultaneously2
and may transition from a neuroprotective phenotype at symptom onset to become more
neurotoxic later in the disease course.3
There are many signaling pathways governing microglial phenotype, including a complex
formed by TREM2 (MIM 605086) and TYROBP (also known as DAP12, MIM 604142).4
Activation of TREM2/TYROBP results in a potentially neuroprotective microglial state, with
improved phagocytosis of apoptotic cellular debris and down-regulation of inflammatory
cytokines.5 The importance of signaling through TREM2/TYROBP is made clear by the fact
that recessive mutations in either gene cause early onset frontotemporal-like dementia, either in
isolation6 or as part of the recessive human disease polycystic lipomembranous osteodysplasia
with sclerosing leukoencephalopathy (PLOSL or Nasu-Hakola Disease, MIM 221770).7,8
Furthermore, recent studies have demonstrated that a rare non-synonymous variant in TREM2,
rs75932628 (encoding p.R47H) is a strong risk-factor for Alzheimer’s disease (AD), another
neurodegenerative disease characterized by microglial activation.9–13 Other studies have
implicated the same variant in frontotemporal dementia and Parkinson’s disease.14,15 It has been
hypothesized that this variant impairs TREM2/TRYOBP signaling, thereby blunting
neuroprotective microglial activation and exacerbating the disease process.9,11
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In this study we demonstrate that p.R47H is a risk factor for sporadic ALS, and
demonstrate upregulation of TREM2 in human ALS spinal cord and in spinal cord from the
G93A mouse model of SOD1 ALS.16

6.3 Methods
6.3.1 Study subjects and TREM2 p.R47H genotyping
923 sporadic ALS (SALS) subjects and 1854 normal controls, all of self-reported nonHispanic white background, were included and provided written informed consent at their
contributing institution. Diagnoses of probable or definite ALS were made by neuromuscular
specialists according to El Escorial criteria (Washington University in St. Louis, n= 273;
Virginia Mason Medical Center, n=143; Methodist Neurological Institute, n= 47; Coriell plates
NDPT025, NDPT026, NDPT100, NDPT103, NDPT106, n=460). Control subjects were without
ALS, Parkinson's disease, or dementia and were collected from ongoing studies (Washington
University, n=1390) or Coriell panels (NDPT020, NDPT079, NDPT082, NDPT095, NDPT096,
n=464). 55% of SALS cases were male and age at DNA collection was 61.0±11.6 years old
(mean ± stdev), while the control cohort was 44% male and 68±13.6 years old (mean ± stdev).
An additional control group of 25,023 individuals of European or European American descent
was collated from published studies (Table 1) and from the unrelated European Americans (EA)
genotyped by whole-exome sequencing as part of the NHLBI’s Exome Sequencing Project or
ESP (http://ESP6500.gs.washington.edu/ESP6500/ [1 Dec 2013]).) Icelandic controls were not
included given the isolation of the population and significantly higher MAF at rs75932628.9
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DNA was extracted from blood or saliva using standard methods and genotyped for
rs75932628 (TREM2 p.R47H) using a custom KASPar (KBioscience) assay.12 Genotype call
rate was 99.7% in both cases and controls. p.R47H carriers were validated by sequencing.

6.3.2 TREM2 expression analysis
Expression in human lumbar spinal cord: Total RNA was extracted from snap-frozen
transverse sections of lumbar spinal cord of 18 autopsied subjects with ALS (Table 2) and 12
controls without neurological disease using the miRNeasy kit (Qiagen). Extracted RNA was
quantified and 40ng was used as input for the Express One-Step Superscript qRT-PCR Universal
(Invitrogen: 11781-200) with validated Taqman assays for human TREM2 and three endogenous
controls, GAPDH, PPIA, and RPLPO (Applied Biosystems 4331182, 4333764F, 4333763F,
4333761F respectively). Reactions were run in duplicate on an ABI 7500 fast thermocycler.
TREM2 expression was normalized to the geometric mean of the three endogenous controls. 10
subjects had provided separate informed consent for genetic analysis, but none were found to
carry the p.R47H variant.

Expression in mouse spinal cord: Total RNA was extracted from saline-perfused and snapfrozen spinal cords of 8 end-stage SOD1G93A transgenic mice (Jackson Lab B6.CgTg(SOD1*G93A)1Gur/J) and 6 negative littermate controls. TREM2 expression was quantified
using a mouse-specific TREM2 Taqman assay (Applied Biosystems 4331182) and normalized to
the endogenous control SMRT using primers and probe from IDT DNA (Probe:
AGACGTCTCACACAAGGAAGGACTCGCC, Forward primer:
GGGTATATTTTTGATACCTTCAATGAGTTA, Reverse primer
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TCTGAAACAGTAGGTAGAGACCAAAGC). Reactions were run in duplicate on an ABI
7500 fast thermocycler.

6.3.3 Exome Sequencing
Whole exome sequencing was generated from 735 patients either at Washington
University or at Duke University as part of a large ALS exome sequencing initiative.17
Sequences were aligned to the human genome reference Hg19 using Novoalign
(http://www.novocraft.com) and variants were called by Samtools.18 PCA analysis was used to
identify 608 subjects of European ancestry that were used for analysis. Variants in the TREM
locus (chr6: 41116999-41254457) and TYROBP (chr19: 36395303-36399211) were queried
using vcftools.19 Variants in these regions were then annotated using SeattleSeq
(http://sngs.washington.edu/SeattleSeqAnnotation131/), and filtered them to included variants
that resulted in coding changes in any transcript of a particular gene. Variants in the same
genomic regions were extracted from the non-Finnish European population in the ExAC
database (Exome Aggregation Consortium, Cambridge, MA, http://exac.broadinstitute.org
[May,2015]) for comparison of variant frequencies.

6.3.4 Statistical analysis
All statistics were computed using R version 3.0.1 except as noted. Fisher’s exact test
was used to compare proportions of p.R47H carriers in cases and controls. Comparisons of
TREM2 expression utilized student t-tests, while correlations between TREM2 expression and
subject characteristics utilized Spearman correlations (continuous variables) or Mann-Whitney U
(dichotomous variables). Logistic regression was performed in PLINK with age and gender as
covariates using cases and controls for whom this data was available (913/920 of ALS subjects
and 1803/1848 of controls). All tests were two-tailed, with the significance level set at p=0.01 to
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correct for multiple comparisons. Single-variant association tests in the TREM family genes
were performed using fisher’s exact tests. Gene-based tests were performed using SKAT as
described in chapter 3.

6.4 Results
6.4.1 TREM2 p.R47H in sporadic ALS
1.09% (10/920) of sporadic ALS subjects and 0.162% (3/1848) of normal controls were
heterozygous carriers of the p.R47H variant, showing a significant enrichment in ALS
(OR=6.77; 95% CI 1.86-24.65; p=0.0016). No cases or controls were homozygous for this
allele. Because the proportion of p.R47H carriers in the population declines with age7 and our
cases were younger than controls, we also analyzed our data by logistic regression with age and
gender as covariates. This produced a similar risk estimate (OR=7.38; 95%CI = 1.95-27.9, p=
0.0032). To provide a more conservative estimate of effect size, we also compared our sporadic
ALS cohort to an aggregate control population of European ancestry gleaned from published
studies and databases (n=25,023, Table 6.1). We again observed an enrichment in sporadic ALS,
albeit with a lower effect size (OR=2.81; CI 1.31-5.41; p=4.8x10-3). A prior study of a smaller
cohort of North American ALS patients found a non-significant but increased frequency in cases
versus controls (0.7% vs. 0.45%).14 A combined analysis of this study with ours compared to all
available controls also showed a significant association (OR=2.40; 95%CI=1.29-4.15; p=4.1x103

), confirming that TREM2 p.R47H is a risk factor for ALS. TREM2 p.R47H carriers in our

cohort showed no difference in age of symptom onset, site of first symptom, or in survival
compared to those without. However, the rarity of the variant limited our power to detect such a
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difference. A larger cohort of p.R47H carriers with ALS will be required to definitively
determine effects on disease parameters.

ALS

Controls

Table 6.1 TREM2 p.R47H carriers in published cohorts and this study. Abbreviations: MAF= minor allele
frequency; ESP-EA= Exome Sequencing Project European American; N. America=North American

Cohort
ESP-EA
Spain12
Georgia, USA9
Germany9
Netherlands9
Norway9
N. America/UK11
Utah, USA13
France10
N. America/Ireland/Poland14
This Study (N. America)
Total Controls
This Study (N. America)
N. America14
Total ALS Subjects

No. Subjects
4,300
550
402
1,891
4,950
2,484
5,166
2,540
783
1,957
1,848
26,871
920
765
1685

p.R47H carriers
22
0
1
7
15
8
20
12
4
8
3
100
10
5
15

MAF (%)
0.26
0.00
0.12
0.19
0.15
0.16
0.19
0.24
0.26
0.20
0.08
0.19
0.54
0.33
0.45

6.4.2 TREM2 expression in spinal cords from humans with ALS and
SOD1G93A mice
In collaboration with Tim Miller’s lab, we examined spinal cord expression of TREM2 in
lumbar spinal cord sections from 18 subjects with ALS and found a 2.8-fold upregulation
compared to controls (p=2.8x10-4; Figure 6.1 panel A). Expression levels did not correlate with
age of onset, site of symptom onset, or presence of a known disease-causing mutation (Table
6.2). However, the degree of upregulation showed a modest inverse correlation with disease
survival that was not statistically significant after correction for multiple comparisons. Because
markers of microglial activation are also upregulated in models of SOD1 ALS20, we evaluated
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TREM2 expression in SOD1G93A transgenic mice and found a 13-fold increase compared to nontransgenic littermates (p=2.8x10-9; Figure 6.1 panel B).
Table 6.2 ALS autopsy subjects studied for TREM2 expression in lumbar spinal cord.
a Survival defined as symptom onset to death or full-time ventilation.
b 3 subjects had SOD1 mutations (A4V, G85R, I133T) and 3 had C9ORF72 repeat expansions.
c Spearman correlation, unadjusted for multiple comparisons.
d Mann-Whitney U rank test, unadjusted for multiple comparisons.

Demographic Category
Age at onset (years, n=17)
Survivala (months, n=18)
Postmortem interval (hours,
n=11)

Site of onset (n=16)
Genetic causeb (n=18)

Metric
Mean ± stdev (range)
61±13 (29-75)
31.3±28.0 (4Mean ± stdev (range)
108)

Correlation
r=-0.03

P-value
0.9c

r=-0.49

0.04c

r=-0.45

0.17c

Mean ± stdev (range)

12.4±7.5 (2-28)

% Bulbar (n)
% With known gene

31 (5)

0.21d

33 (6)

0.21d

(n)

Figure 6.1 TREM2 expression is increased in human ALS and SOD1G93R mouse spinal cord. TREM2 expression
was measured by qPCR in A) lumbar spinal cord sections from 18 ALS subjects and 12 controls and normalized to
the geometric mean of three endogenous control genes. B) In mice, expression was measured in spinal cords from 8
SODG93R mice and 6 wild-type littermates with normalization to an endogenous control. p-values were calculated
using two-tailed student’s t-test.

6.4.3 Additional mutations in TREM2 and TREM family genes
We used whole-exome sequences of ALS patients to determine if there were additional
TREM2 mutations that conferred a risk of ALS. There were 7 coding variants in TREM2 in the
exomes of 608 ALS patients with European ancestry, none of which were novel (table 6.3).
When compared to the population of non-Finnish Europeans (NFE) from the ExAC browser, no
variants were significantly associated with disease status. Although there is overlap between the

samples included in whole exome sequencing and the cohort we originally genotyped, the
p.R47H signal did not replicate in this set. The majority of the association came from the Coriell
samples which were not included in these exomes. The frequency of rare coding variants in
TREM2 was 0.020 in ALS patients and 0.021 in the NFE population in the ExAC browser. The
distribution was not different by SKAT analysis (p=0.99).
Table 6.3 Variants in TREM2 detected by exome sequencing.

Allele Counts
Chr
6
6
6
6
6
6
6

Hg19
Amino
Alleles
SNP ID
Position
Acids
(Ref/Alt)
41129252 R47H
rs75932628
C/T
41129207 R62H rs143332484
C/T
41129133 D87N rs142232675
C/T
41129105 T96K
rs2234253
G/T
41127543 H157Y
rs2234255
G/A
41126655 L211P
rs2234256
A/G
41126429 W191X rs2234258
C/T

Alt
ALS
3
14
4
1
1
1
1

Ref
ALS
1215
1226
1238
1241
1241
1239
1241

Alt
NFE
172
762
119
57
20
64
19

Ref
NFE
66102
65900
66609
66671
66546
66670
62339

p-value
1
1
0.292
1
0.322
1
0.326

There are 4 additional genes TREM1, TREML1, TREML2 and TREML4 in the TREM
family of genes, all located in the same genomic region as TREM2. The SNP rs3747742 in the
related gene TREML2 has been shown to be protective in Alzheimer’s disease.21 We looked for
variants in these four genes in addition to TYROBP.
We saw no difference in the frequency of rs3747742 (MAF=29.6% in ALS and MAF=
29.9% in NFE). Aside from this SNP, we only analyzed rare variants that were less than 1%
frequency in controls (table 6.4). There were a total of 8 novel variants in these genes, all of
which were found in a single individual. None of the variants passed the corrected significance
threshold (0.002). The variant that came closest to significance was rs112680060 in TREML4
(OR=1.9, 95% CI=1.15-3.08).

142

Table 6.4 Variants in TYROBP, TREM1, TREML4, TREML2, and TREML1.
Allele Counts
Gene

Chr

Hg19
position

Amino
Acids

SNP ID

Alleles
(Ref/Alt)

Alt
ALS

Ref
ALS

Alt
NFE

Ref
NFE

pvalue

TYROBP

19

36398357

A74T

.

C/T

1

1236

0

65890

0.0184

TYROBP

19

36398414

V55L

rs77782321

C/A

13

1216

637

65217

0.6602

TREM1

6

41250175

P122A

.

G/C

1

1241

0

66466

0.0183

TREM1

6

41248810

C163F

rs201082267

C/A

1

1231

14

66722

0.2400

TREM1

6

41243926

F214L

rs2234245

G/C

1

1241

29

66695

0.4250

TREML4

6

41196169

A2S

rs112680060

G/T

19

1223

490

61320

0.0091

TREML4

6

41197301

T146K

rs9471515

C/A

1

1241

43

66687

0.5559

TREML4

6

41204306

G197S

.

G/A

1

1241

0

66662

0.0183

TREML2

6

41166063

V54F

rs147506354

C/A

4

1238

83

66653

0.0755

TREML2

6

41162556

R131K

.

C/T

1

1237

0

64452

0.0188

TREML2

6

41162395

A185T

.

C/T

1

1241

13

66493

0.2282

TREML2

6

41162371

T193A

rs145455750

T/C

3

1239

167

66287

1.0000

TREML2

6

41162204

S248R

rs115991880

G/T

4

1238

212

26352

0.0668

TREML2

6

41162173

P259T

.

G/T

1

1237

0

12334

0.0912

TREML2

6

41160572

V285I

rs35521209

C/T

1

1241

11

56969

0.2280

TREML1

6

41121702

E57A

.

T/G

1

1239

0

66302

0.0184

TREML1

6

41118614

V171I

rs41273760

C/T

2

1236

7

66627

0.0110

TREML1

6

41118000

M207T

rs35929443

A/G

3

1239

114

65144

0.4838

TREML1

6

41117594

D228E

rs138237630

A/T

4

1226

282

66444

0.8232

We compared total variant burden in each of these genes using SKAT. TREML4 was the
only gene that was significant (table 6.5). This appears to be mainly driven by the higher
frequency of rs112680060 in ALS.
Table 6.5 SKAT variant burden testing.

Gene
TREM2
TYROBP
TREML2
TREM1
TREML1
TREML4

Total variant
Total variant
frequency (%) frequency (%)
ALS
NFE
2.01
2.13
1.12
1.17
1.21
0.90
0.24
0.28
0.80
0.78
1.69
1.05
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SKAT
p-value
0.99
0.86
0.26
0.77
0.51
0.003

6.5 Discussion
Our study demonstrates that a rare variant in TREM2 (p.R47H), more than doubles the
risk of ALS. In addition to identifying a novel risk factor for ALS, this finding provides the first
link between genetic variation and microglial activation in ALS pathogenesis. This is important
in light of a recent study demonstrating that higher degrees of microglial activation on
pathological examination were correlated with both the degree of upper motor neuron symptoms
and a more rapid disease progression.22 Interestingly, our evaluation of TREM2 expression in
ALS spinal cord showed a similar trend, with higher levels of TREM2 correlating with shorter
survival. Furthermore, our finding that TREM2 expression is also increased in spinal cords from
SOD1G93A mice is congruent with recent studies of isolated microglia from this same model2 and
suggests that studies of microglial activation in this model may provide insights relevant to
human ALS.
We identified no novel variants in TREM2 by exome sequencing and none of the known
variants were associated with disease state. Interestingly, we did not identify any p.R47H carriers
in the additional subjects we analyzed; all three p.R47H carriers were previously discovered in
our original cohort. We did not have ages of the controls used for this analysis and were
therefore not able to control for possible changes in frequency with age as we did for p.R47H. It
is possible that we were unable to detect associations because of this.
p.R47H was first shown to increase risk for Alzheimer’s disease with subsequent
associations with frontotemporal dementia and Parkinson’s disease.9–14 How the p.R47H variant
affects TREM2 function and predisposes to neurodegeneration is currently unknown. Because
TREM2 signaling mediates potentially neuroprotective microglial activities (including
phagocytosis of apoptotic cells and secretion of anti-inflammatory cytokines), one model
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hypothesizes that p.R47H is a loss-of-function allele. Inadequate clean-up of cellular debris and
counter-productive inflammation would predispose to symptomatic disease. The p.R47H variant
is located in the extracellular domain of TREM2 where it could interfere with binding to
unidentified ligand(s) or disrupt signaling through its receptor complex partner TYROBP.
We also looked for variants in the four other genes in the TREM family of membrane
receptors, all of which are located in the same genomic location with TREM2.23 There was an
increase in variant burden in ALS in TREML4 with the variant rs112680060 contributing most of
the signal. TREML4 is expressed abundantly in the spleen and recognizes apoptotic and necrotic
cells.24 Like TREM2, TREML4 associates with TYROBP.24 Although TREML4 is not normally
expressed in microglia, it was shown to be significantly upregulated in microglia in response to
damage to dopaminergic neurons.25 There were no associations with any of the other TREM
genes or with TYROBP.
As dysregulated TREM2 signaling confers risk for several neurodegenerative disorders,
insights gleaned from the study of TREM2 in ALS are likely to be applicable to other diseases
and vice versa. This includes the important possibility that manipulation of TREM2 signaling or
microglial activation would be a worthwhile therapeutic strategy.
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Chapter 7
Conclusions and future directions
7.1 Contribution of known ALS genes
Amyotrophic lateral sclerosis (ALS) is a degenerative disease of the motor neurons which
is universally fatal. Over 20 genes have been identified that cause ALS. Mutations in these genes
explain up to 70% of ALS cases with a family history of disease (FALS), with hexanucleotide
repeat expansions accounting for 40% of cases alone. The vast majority of ALS cases have no
family history and are considered sporadic (SALS). Some of these cases also have mutations in
FALS genes, with about 6% caused by C9ORF72. Current hypotheses for genetic contributions
to SALS include oligogenic inheritance, where mutations in multiple ALS genes are required for
disease, and rare variants in ALS genes that increase risk of ALS.
Using pooled-sample sequencing we investigated variations in 17 known ALS genes and
found that potentially pathogenic mutations in 64.3% of familial ALS cases and 27.8% of
sporadic ALS cases. This was higher than any previous study and while this is possibly due to
genetic heterogeneity it is more likely due to differences in which genes were included. In the
past, only the most commonly mutated genes in ALS were screened in large cohorts (SOD1,
TARDBP, FUS, ANG, OPTN, VCP, and recently C9ORF72). The decreasing cost of nextgeneration sequencing enabled our pooled sequencing strategy and other targeted sequencing
techniques to screen larger numbers of genes.1,2
Furthermore, the proportion of potentially pathogenic mutations was highly influenced by
the definition of which mutations are considered pathogenic. The use of common guidelines in
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reporting novel mutations will improve consistency and allow us to make accurate comparisons
between studies.3 Several criteria should be considered when evaluating potentially pathogenic
variants including the segregation of the variant with affected members in a family, absence of
the variant in control populations, and functional evidence. Due to the late onset of disease, we
are less likely to have DNA from parents and other family members to test for segregation.
Therefore variant frequency in controls and functional evidence will be more important in the
assessment of pathogenicity.
We considered all mutations that had a frequency of less than 1% in control databases to
be potentially pathogenic. Other studies typically either exclude all variants detected in public
databases or internally sequenced controls. We found that excluding all control database variants
removed several mutations that have previously been reported to cause ALS while all of these
remained when using a threshold of 1% minor allele frequency. The presence of these mutations
in controls is likely a reflection of the small number of controls used when they were identified,
prior to our knowledge of the abundance of rare variation in all individuals.4,5 Alternatively, the
presence of these mutations in controls could represent lower penetrance alleles or contamination
with individuals at-risk for ALS but not yet manifesting symptoms.
Statistical significance is important to consider when comparing novel variants to control
populations; however most studies lack the power to detect statistically significant associations
of rare variants. We compared frequencies of all rare variants identified in our sporadic ALS
cohort and did not find any that were significantly more common in ALS. This includes
mutations that are known to be pathogenic, such as SOD1 mutations p.A5V and p.I114T.
Additionally, some genes are more tolerant to variation than others and therefore mutations
would be less likely to have an effect.6,7 Gene-based test such as SKAT take this into account by
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comparing the mutation frequencies across a region in cases and controls and can show whether
a gene is more commonly mutated in affected individuals compared to the mutation frequency in
the general population. In a gene-based test looking at total variation in SOD1, we did achieve
statistical significance, however this was the only gene that did. This type of collapsing method
can be further refined to identify specific domains of a gene or expanded to identify entire
pathways and networks that are more frequently mutated in disease.
There are several in silico pathogenicity prediction algorithms that can be used to
prioritize variants for follow-up, however we have not used them here to exclude potentially
pathogenic variants. It is important to consider the specific gene and disease under investigation
when using these in silico methods. These algorithms evaluate pathogenicity of variants using
evolutionary conservation and changes in structural and biochemical properties. Drastic changes
in amino acid properties are, however, more likely to result in early onset disease8, therefore a
mutation involved in a late onset disease such as ALS might be more likely to be predicted as
benign. Furthermore, mutations that result in late onset disease are not under purifying selection
and the positions will not be as highly conserved, again making them more likely to be predicted
to be benign. There is also evidence that different in silico predictions and combinations of
multiple predictions are more accurate for different genes.9
Experimental evidence will be necessary to validate the predicted functional effects of
potentially pathogenic variants. The use of induced pluripotent stem cells (iPSCs) and direct
conversion of adult tissues such as fibroblasts into other tissue types such as neurons or
microglia will be particularly valuable to show the effects of mutations in the context of the
patient's entire genome. Advances in genome editing technologies such as CRISPR/Cas9 will
allow us to determine if a particular mutation is causative by converting it to wild-type and
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observing if this corrects the pathogenic phenotype.10 This technology can also be used to delete
large segments of DNA and could potentially remove the C9ORF72 repeat expansion.11 This
will be particularly interesting in patients with mutations in multiple ALS genes. Based on our
hypothesis that mutations in multiple genes are not required for disease but act synergistically,
we would expect that correcting only one mutation would not fully correct the phenotype.
Despite finding mutations in a higher than expected proportion of subjects, nearly 70% of
our cases remain unexplained. The falling cost of next-generation sequencing has made it
possible to perform whole exome sequencing (WES) on larger numbers of patients to identify
novel genes involved in disease. Recently, our patients were included in an ALS consortium that
sequenced 2869 ALS subjects and identified the gene TBK1 as risk factor.12 As additional WES
data continues to be generated, novel approaches to analysis and refinement of in silico
pathogenicity predictions will be required to tease out meaningful associations from massive
amounts of information. Current analysis focus on the effects of coding variants and ignores the
hundreds of mutations in regulatory regions and microRNAs. Data generated from the ENCODE
project, which aims to annotate all functional elements of the human genome13, will help us
interpret variants that may be causing disease through changes in gene regulation.

7.2 C9ORF72
One of the intriguing aspects of the C9ORF72 repeat expansion is its prevalence in
sporadic ALS. We pursued two different avenues that would give us insight into this observation
and also help us understand their pathogenicity. The first was to determine whether all expansion
carriers were descended from a single expansion event. Evidence of a single founder event
would indicate that the sporadic ALS carriers were cases of incomplete penetrance in the parents.
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We identified a rare variant rs147599399 on the risk haplotype that was present in both
some expansion carriers and some non-expansion carriers, showing that the expansion arose at
least twice in history. This SNP also influenced disease presentation by extending survival in
expansion carriers. This finding shows that the risk haplotype, marked by rs3849942, is one that
is permissive to expansion and that both rs147599399 and rs3849942 could be cis-acting
modifiers of the expansion.
Further sequencing of the risk haplotype in C9ORF72 expansion carriers may identify
more rare variants that would provide further evidence of multiple expansions. One group used
targeted capture to sequence the risk haplotype and did not identify rs147599399 or other
variants that would provide evidence against a single founder, however all subjects were of
Northern European ancestry.14 It is possible that expansions in subjects of Northern European
ancestry are indeed descended from the same founder and that more heterogeneous populations
such as ours are needed to reveal rare haplotype variants. Furthermore, it may be that
rs147599399 is not itself cis-acting modifier of the expansion. Sequencing the full risk haplotype
may reveal that rs147599399 is in linkage disequilibrium (LD) with the true modifier and may
identify additional cis-acting modifiers.
Determining the effects of these SNPs is an important step in comprehending the origin
of repeat expansions in C9ORF72. Studies have shown that the distance between the repetitive
sequence and origin of replication is important factor in instability of trinucleotide repeats15 and
one study showed that a SNP on the predisposing haplotype of the FMR1 expansion fell within a
mapped replication origin altering the timing of DNA replication in that region.16,17 This could
be the mechanism through which rs3849942 (or a different SNP on the risk haplotype)
predisposes the C9ORF72 repeat toward further expansion.
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There are a few approaches that use next-generation sequencing to identify replication
origins genome-wide. Repli-seq involves labeling newly synthesizes DNA in dividing cells with
BrdU, sorting cells by cell-cycle progression and sequencing the BrdU labeled DNA. This
provides a map of the replication timing through the cell cycle.18 However, due to the differences
in replication timing between different cell lineages18 and the fact that we observe contraction of
the repeat in the BAC, it is unclear whether observations in cell culture models will be an
accurate representation of how the repeat locus behaves in disease. Another technique of
observing replication origins uses ChIP-Seq targeting a component of the origin replication
complex (ORC1) to identify replication origins.19 This method was performed using cell lines,
however could potentially be used on frozen patient tissues.20
Cis-acting modifiers in other repeat expansion disorders include altered methylation
status and formation of secondary structures.21–24 Methylation profiles and G-quadruplex
structures, which are present in expanded GGGGCC repeats25, can both be evaluated using
frozen patient tissues.26 The downstream effects of these changes, such as increased or decreased
transcription, alternative splicing, and changes in RAN translation levels of C9ORF72, can also
be compared by rs147599399 genotype. RNAseq was recently used to show that C9ORF72
expansion carriers had altered transcription levels and splicing patterns of certain genes
compared to non-C9 ALS subjects.27 It would be interesting to see if transcriptome profiles also
differed by r147599399 genotype within expansion carriers.
Another way we explored the repeat expansion was by using Southern blot analysis to
ascertain expansion sizes. Instability of the repeat expansion could lead to sporadic disease
through anticipation or through somatic instability. Progressive expansion of the repeat through
generations, as is characteristic of anticipation, could produce SALS patients with parents whose
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expansions do not meet a threshold for pathogenicity. Somatic instability could result in SALS
patients with larger expansions in CNS tissues leading to neurodegeneration whereas their
unaffected parents would not have larger expansions in their CNS tissues.
Instability of the repeat in control families from the CEPH panel was shown with a
change from 21 repeats in paternal grandparent to 22 repeats in the father to 20 repeats in his
son. All families with changes in repeat size between generations had more than 10 repeat units
and all unstable transmissions were paternal. 28 To our knowledge, we have shown the first
evidence of instability in families with full-length expansions. Unstable transmissions came from
paternal and maternal lines. This instability was not the typical pattern that is seen in anticipation
since the repeat was not always expanding between generations, however there are other repeat
expansion disorders with anticipation that have both expansions and contractions as well.29,30
Somatic instability of the repeat has been shown in multiple reports. All of these studies
consistently show that expansions in the blood are smaller than most brain regions except for the
cerebellum.28,31–33 We observed the same somatic instability, but did not identify any
correlations between expansion size and clinical features in any of the observed tissues. Other
studies have produced mixed results regarding the effect of expansion size in specific tissues on
age of onset and survival. Beck et al. found expansion sizes in blood to be positively correlated
with age of onset in a variety of neurodegenerative diseases including ALS.28 Van Blitterswijk et
al. found no correlations between age of onset or survival in ALS patients, but did find a two
associations in patients with frontotemporal dementia: a positive correlation between expansion
size in the frontal cortex and age of onset in and an association between larger expansions in the
cerebellum with reduced survival.31 The Nordin et al. study included the largest number of
tissues and only found correlations with expansion sizes in the cerebellum and parietal lobe.
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Smaller expansions in the cerebellum and parietal lobe were associated with earlier age of onset
in ALS while larger expansions in the parietal lobe were associated with shorter survival in ALS
patients and the overall cohort.32 Additional studies will be required to clarify these findings.
We observed no difference in expansions in blood-derived DNA of affected and
unaffected carriers, although it is possible that affected carriers have larger expansions in CNS
tissues or more specifically in motor neurons compared with unaffected carriers. These data
suggest that expansion size is not the only factor in pathogenicity. There is evidence that
environmental stress can induce trinucleotide repeat instability in cells34 so it is possible the
cellular stress in motor neurons could induce further expansion and result in degeneration of
those neurons. There could also be other cis- or trans-acting genetic factors that interact with
expansions and reduce their penetrance. For example a common variant in TMEM106B protects
against fronto-temporal dementia in expansion carriers35 and intermediate expansions in ATXN2
predispose towards motor neuron degeneration.36
One aspect of the expansions that we were unable to study was whether the repeat
sequence is pure or contains interruptions of non GGGGCC units. Interruptions in the repeat
sequence of other expansion disorders reportedly stabilize expansions and prevent them from
continuing to expand by preventing slippage of DNA replication machinery during cell
division.37–39 Due to the length and GC content of the repeats, they cannot be sequenced by
conventional methods. Real-time long-read sequencing was recently used to sequence through
expanded CGG repeats in the FMR1 gene showing the presence of AGG interruptions in the
sequence and simultaneously determining the size of the expansions.40 Preliminary studies
sequencing the BAC on the MinIon long-read sequencing platform were able to generate a size
distribution for expansion length (Figure 7.1), but base-calling is not yet accurate enough to
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detect sequence interruptions. This method requires the preparation of sequencing libraries
containing the repeat, so while it can be used to sequence the BAC, we are working on
developing methods to isolate expanded C9ORF72 alleles from patients genomic DNA for
sequencing.

Figure 7.1 Preliminary sequnecing of a C9ORF72 BAC on the MinIon sequencing platform. A. Southern blot showing the size of
the expansion in the BAC compared to a BAC with an unexpanded allele (~30 repeats in the expanded BAC). B. Histogram of
repeat lengths from a MinIon sequencing run. The peak expansion size was 150bp longer than wild-type, corresponding to ~28
repeats.

7.3 Neuroinflammation
In order to find risk factors that are associated with sporadic ALS, we selected TREM2 as
a candidate gene. TREM2 encodes the triggering receptor expressed on myeloid cells 2 and is
involved in activation of microglia.41 The rare p.R47H SNP was shown to be associated with
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Alzheimer’s disease which also presents with microglial activation,42–46 therefore we genotyped
this SNP in our cohort.
We showed that this same SNP was significantly associated with disease in our SALS
cohort. TREM2 expression was increased in spinal cords from ALS patients and SOD1G93A mice.
It is unclear whether this is a specific effect of TREM2 or a reflection of the recruitment of
microglia to the site of motor neuron injury. We were unable to determine if p.R47H had any
effect on expression levels. We hypothesized that p.R47H was a loss of function mutation that
resulted in an inability of microglia to remove cellular debris. A recent study of TREM2 in AD
showed that the SNP did not alter the expression or signaling ability of TREM2, but reduced its
ability to bind ligands including phospholipids.47
In order to determine if there were other mutations in the TREM family that were
associated with ALS, we looked for variants in TREM2, TREM1, TREML1, TREML2, TREML4,
and the binding partner of TREM2, TYROBP. There were no additional variants in TREM2 or
any of the other genes that were significantly associated with ALS. Variants in TREML4
approached significance, mainly due to the SNP rs112680060. TREML4 is also involved in
recognition of apoptotic cells and associates with TYROBP48 and while it is not normally
expressed in microglia, it was upregulated in response to neuronal damage.49 A role for TREML4
in ALS has not been reported, so it will be important to see if TREML4 is expressed in spinal
cords of ALS patients and if the rs112680060 SNP has any effect on its expression. If TREML4
acts similarly to TREM2 this SNP could alter the ability of TREML4 to recognize degenerating
neurons for clearance.
Current studies in our lab are attempting to clarify the role of TREM2 in ALS. We are
measuring the expression levels of TREM2 mRNA levels in additional spinal cords to confirm
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our initial observations. In addition we are measuring TREM2 in blood and CSF from patients to
determine its viability as an ALS biomarkers. Mouse models exploring the effects of TREM2
genetic knock-out in the SOD1G93A are underway to explore the role of TREM2 in motor neuron
degeneration. Additionally anti-sense oligos are being generated to knock-down TREM2
expression in symptomatic SOD1G93A mice to study the specific effects of TREM2 in disease
progression.
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